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ABSTRACT 
Next Generation Sequencing (NGS) technologies have greatly 
impacted every field of molecular research, reducing costs and 
simultaneously increasing throughput of DNA sequencing. These features, 
together with technology’s flexibility, have open the way to a variety of 
applications, especially for the study of the molecular basis of human 
diseases.  
So far, several analytical approaches have been developed to 
selectively enrich regions of interest from the whole genome, both to 
identify germinal and/or somatic sequence variants. All of these have 
assessed their potential in research area and are now being improved also in 
routine molecular diagnostics. Thanks to the improvement due to NGS 
methods introduction, also the metagenomic field has achieved very 
exciting results, increasing our knowledge about the microbiome and its 
mutually beneficial relationships with the human host. If microbiome plays 
a role in the maintenance of a healthy status, it is conceivable to suppose 
that its quantitative and/or qualitative alterations could lead to pathological 
dysbiosis, as shown in an increasing number of intestinal and extra-
intestinal diseases.  
The aim of this project was to use NGS-based strategies to study the 
molecular basis of human diseases. In particular, two analytic approaches 
were used: DNA sequence capture and metagenomics. 
A DNA sequence capture approach was used to analyze a large panel 
of genes possibly related to inherited cardiomyopathies. The obtained 
results indicate that this approach is useful to analyze, in a time and cost 
effective manner, heterogeneous diseases allowing the identification not 
only of the disease-causing mutation, but also of other variants involved in 
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disease-phenotypic expression. Finally, methods reliability was higher than 
traditional, currently used techniques. All the above data indicate that this 
validated NGS-based approach can be used to improve the molecular 
analysis of inherited cardiomyopathies, such as of other inherited diseases, 
also in routine diagnostic settings. 
With regard to metagenomics, a 16S rRNA pyrotag analysis was 
carried out to deeply investigate the gut microbiome composition of Crohn 
and celiac diseases. Specific microbial signatures were identified in the 
patients. Moreover, the effects of Crohn nutritional therapy on gut microbial 
composition were also verified. These results suggest a role of gut 
microbiome in diseases pathogenesis and could, in turn, make possible to 
develop novel diagnostic, prognostic and, most important, therapeutic 
strategies. 
Taken together, all the above results indicate that the used NGS-
based procedures can be easily applied to increase our understanding of the 
molecular basis of human diseases and that they can be useful also for 
routine diagnostic purposes.  
 
 
 
Keywords 
Next generation sequencing, molecular diagnostics, metagenomics, 
inherited cardiomyopathies, Crohn disease, celiac disease. 
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I. INTRODUCTION 
 
The process of determining the exact order of the nucleotides in a 
DNA molecule or in a genome is defined as “DNA sequencing”. This 
simple definition is enough to understand how, techniques able to perform 
this operation have radically changed the course of molecular research in all 
its fields of application. 
In the last 30 years, the so-called Sanger sequencing has been the 
most widely used sequencing technology worldwide [1]. This method, 
developed in the ‘70s by Frederick Sanger, thanks to continuous 
improvements in technology performances, reached its peak with the 
Human Genome Project (HGP), which, in 2001, elucidated the first entire 
human genome [2,3]. Now, the Sanger sequencing procedure is completely 
automated; however, it is a single amplicon method and, as such, it is 
expensive and time consuming. Starting from these points, there was the 
need to develop novel sequencing methods able to overcome Sanger limits 
and answer to the increasing requests of great amounts of high quality 
sequencing data, both in a faster and cheaper fashion. 
To address the above mentioned issues, in the last ten years, novel 
technologies, called “next generation sequencing” (NGS), have become 
available. NGS methods have dramatically increased the throughput of 
DNA sequencing, simultaneously reducing its costs [4]. Just to give the idea 
of what this means, it took more than 10 years to elucidate the first human 
genome sequence and it cost 3 billion $. Using NGS instruments, the entire 
genome sequence of an individual has been elucidated in only 1 year and at 
a much lower cost [5]. It is expected that the sequencing of the entire 
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genome of an individual will cost about 1,000 $ in a near future (Figure 1) 
[6]. 
 
 
Figure 1. Impressive reduction of DNA sequencing costs. The graph 
shows that the introduction of NGS dramatically dropped sequencing costs 
respect to the hypothetical prevision of the Moore’s Law, based on the 
prevision of exponential computing costs reduction [6]. 
 
 
These aspects, coupled to the technologies versatility, have open the way to 
the massive NGS diffusion in every field of molecular research and to the 
begin of the so called “-Omics” era. 
 
1.1 Next Generation Sequencing Technologies 
Next Generation Sequencing technologies (NGS) have been defined 
as the next phase of DNA sequencing evolution since they allow single 
laboratories to sequence entire genomes in a few time and at very 
competitive costs [7]. 
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Different NGS platforms have been developed so far, each one 
showing specific advantages and limitations. However, until now three of 
them has had the largest diffusion: i) the Roche 454 Genome Sequencer 
FLX (http://www.my454.com/); ii) the Illumina HiSeq 
(http://www.illumina.com); and iii) the Life SOLiD 
(http://www.lifetechnologies.com/). In general, samples’ preparation 
through these platforms is made up of three main analytic steps: i) the 
generation of a single stranded DNA (sstDNA) library; ii) the library 
amplification; and iii) the sequencing reactions. In addition, data analysis 
using specific bionformatic pipelines has to be carried out (Figure 2).  
 
 
Figure 2. Overview of the sample preparation workflow through NGS 
platforms. 
 
 
The library preparation is the most flexible step in the entire 
procedure. It depends on the kind of project, on the nature of the biological 
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samples used as source, and on the question/s you are looking to address. 
Several methods have been used for NGS library preparation. Traditionally, 
the analysis of an entire genome is based on the isolation of the DNA and its 
fragmentation using different methods. Otherwise, to analyze selected 
genomic regions, a number of enrichment procedure, both PCR-based and 
PCR-independent, are available [8]. Finally, it is also possible to analyze the 
whole RNA or RNA subpopulations [9]. At the end of the library 
preparation (independently from the used protocol) a population of sstDNA 
fragments, homogeneous in size and compatible with sequence reads length, 
is obtained. These fragments are modified by the ligation of specific 
adapters (different for each NGS platform), which are required as primers 
for the subsequent amplification and sequencing reactions. The chemistry 
used to carry out these two steps are different for each NGS platform. In 
particular, the library amplification can be obtained by emulsion PCR 
(emPCR) or by solid-phase amplification. In the emPCR, after adapters 
ligation, DNA fragments are captured on the surface of specific beads and 
amplified into the droplets of a water-in-oil emulsion. The ratio between 
library fragments and capture beads is carefully evaluated (titration assay) to 
allow the capture of one DNA molecule per bead. In this way, at the end of 
the amplification cycle, each bead will carry million of copy of the same 
DNA fragment clonally amplified. The emulsion increase the amplification 
specificity since each bead is amplified in its own droplet, reducing cross 
contamination risks. After the amplification, the emulsion is chemically 
broken to recover and enrich the DNA carrying beads (Figure 3, panel A) 
[10]. In the solid-phase amplification, the adapted DNA fragments are 
hybridized to a glass slide to obtain clonally amplified clusters. In this case, 
high density forward and reverse primers are immobilized on the slide and 
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the ratio between them and the library fragments is crucial for cluster 
density and, consequently, for sequencing throughput [8]. In brief, ssDNA 
fragments are hybridized to the glass slide surface, extended by polymerase 
and denatured to obtain ssDNA fragments covalently ligated to the slide 
surface. These obtained ssDNA fragments flip over to form a bridge by 
hybridizing to the primer on the slide and are used as template by the 
polymerase (bridge amplification) (Figure 3, panel B). 
 
 
 
Figure 3. Library amplification’s strategies. DNA library fragments are 
immobilized on the surface of DNA capture beads and amplified into an 
emulsion (A), or hybridized on the surface of a glass slide to do a bridge 
amplification (B) [8]. 
 
 
After the amplification, the libraries are ready to be sequenced. 
Different sequencing chemistries have been developed and optimized by 
each NGS platform, such as pyrosequencing, reversible terminator strategy 
and sequencing by ligation. In the pyrosequencing chemistry the four 
11 
 
nucleotides are eluted one at time in a fixed order. When a nucleotide 
complimentary to the template is added, it is incorporated by the polymerase 
in the elongation strand, releasing a molecule of PPi. The latter is used by 
the sulphurylase to convert the adenosine phosphosulfate in ATP which is 
used by the luciferase to oxidate luciferin. The emitted light is registered by 
a CCD camera and converted in sequence data (Figure 4, panel A) [10]. In 
the reversible terminator strategy, the four nucleotides are labeled each with 
a different fluorescent dye, so that they can be eluted all together during 
each sequencing cycle. The nucleotide complimentary to the template is 
incorporated and, after fluorescence signals registration, it is cleaved 
together with the terminating group becoming available for nucleotide 
adding in the next sequencing step (Figure 4, panel B) [11]. Finally, the 
sequencing by ligation use a mixture of fluorescently labeled octamer 
oligonucleotides that hybridize to the sequence adjacent to the primed 
template. These octamers are two-base-encoded probes in which the 
combination of the first two bases is assigned to a specific dye. So, after the 
hybridization and fluorescence registration, the last three bases of the 
octamer are cleaved to start again with the octamers elution. In this way, at 
the end of the sequencing cycle, two bases each five nucleotides have been 
read on the template strand. At this point, the primer is removed and a 
second ligation cycle is performed using a “n-1 primer”. This primer 
resetting procedure is repeated more time to fill in the gaps in the template. 
This allows each base to be read twice, in two independent ligation reactions 
and using two different primers, ensuring a great accuracy in base calling 
(Figure 4, panel C) [12]. 
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Figure 4. NGS sequencing chemistries. The pyrosequencing process is 
based on the production of light when a nucleotide complimentary to the 
template is added. Since the four nucleotides are not differentially labeled, 
they are eluted one at time in a fixed order to ensure correct base calling. In 
the 454 Roche procedure, the amplified library fragments are annealed on 
the surface of a DNA capture bead. These beads (each carrying million of 
copy of the same DNA library fragment clonally amplified) are deposited 
into the wells of a fiber optic slide (PTP) together with beads carrying the 
pyrosequencing enzymes. In this way, sequencing reactions occur 
simultaneously in all the PTP wells (A). The reversible terminator strategy 
uses four differentially labeled nucleotides eluted together in each 
sequencing cycle. In the Illumina system, the amplified library fragments 
are annealed on the surface of a glass slide (flow cell) to obtain clusters 
simultaneously sequenced (B). Finally, the sequencing by ligation procedure 
use a mixture of fluorescently labeled octamers coupled to a dual color 
code. In the SOLiD procedure the library amplification has been optimized 
from a bead to a slide system (C) [8, 10-12]. 
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The different technical features of each NGS platform account for 
their own strengths and pitfalls, especially in terms of sequencing reads 
length, base calling accuracy and sequencing throughput (Table 1).  
 
Table 1. Comparison of the currently available NGS platforms features. 
NGS 
Platform 
Library 
amplification 
NGS chemistry Read 
lenght 
(bp)* 
Run 
throughput 
(Gb)* 
Run 
time(Days) 
Roche 454 
GS FLX 
emPCR Pyrosequencing 700
†
 0.7 1 
Illumina 
HiSeq 
Solid-phase Reversible 
terminator 
2x125
§
 600 10 
Life SOLiD Solid-phase Sequencing by 
ligation 
2x50
§
 160 8 
Roche 454 
Junior 
emPCR Pyrosequencing 700
†
 0.07 0.5 
Illumina 
MiSeq 
Solid-phase Reversible 
terminator 
2x300
§
 15 2.2 
Life Ion 
Torrent 
emPCR H
+
 Ion 
semiconductor 
400 2 0.34 
NGS, Next generation Sequencing; bp, base pair; Gb, gigabase. 
*Reported considering the highest performances actually available for each 
platform. 
†Average read’s length (up to 1,000 bp). §Paired-end sequencing. 
 
 
The progressive optimization and standardization of NGS procedure 
has lead to a continuous increase of sequencing productivity/run and a 
reduction of sequencing costs, as mentioned above [6]. This, in turn, has 
increased the request for routine NGS-based applications also in clinical 
settings for diagnostic purposes [7]. In this view, the so called NGS “bench-
top” instruments, such as the Roche 454 Junior, the Illumina MiSeq and the 
Life IonTorrent, have been launched on the market promising the same 
sensitivity and accuracy of the biggest instruments, but with instruments 
costs and sequencing run time markedly reduced. From a technical point of 
view, while the Junior and the MiSeq systems use the same chemistries of 
the larger versions, the IonTorrent is completely different from its 
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corresponding larger platform. In fact, it couples the emPCR protocol for 
library amplification to a hydrogen ion semiconductor chip for sequencing 
reactions. In particular, the clonally amplified DNA beads are loaded into 
the wells of this semiconductor device, where the four unlabeled nucleotides 
are loaded. When there is an incorporation event, a hydrogen ion is released 
and the consequent voltage difference is recorded (Figure 5). 
 
 
Figure 5. IonTorrent sequencing chemistry. A nucleotide incorporation 
into the strand of DNA in elongation produce the release of a hydrogen ion. 
The ion charge modify the pH, which is detected by ion sensor and 
converted in sequence data. 
 
 
Taken together, these bench-top platforms are featured by a fast 
turnaround time and a great flexibility in sequencing throughput, 
representing a real chance to combine NGS advantages to a routine 
laboratory use. Their main features in terms of productivity are summarized 
in Table 1. 
In addition to all the above mentioned sequencers, usually defined as 
“second generation”, novel technologies also called “third generation” 
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sequencers are being developed. The main feature of these novel sequencing 
technologies is that they avoid the library amplification step. Therefore, 
library fragments are directly sequenced at a single molecule level with the 
great advantage to avoid PCR biases. Different third generation platforms 
are available, such as the SeqLL HeliScope (http://seqll.com/), the Pacific 
Biosciences PacBio (http://www.pacificbiosciences.com) and the Oxford 
Nanopore (http://www.nanoporetech.com) [13-16]. Also in this case, 
different chemistries have been developed and characterize each platform 
also in terms of capability (Table 2). Even if the potential of these novel 
technologies is really exciting, to date they are not yet currently and 
massively used. It is to be expected that, once the protocols will be 
standardized and the analytic performances improved, they will overwhelm 
the market. 
 
Table 2. Comparison of the Third generation sequencers features. 
Platform Sequencing 
chemistry 
Read 
lenght 
(bp)* 
Run 
throughput 
(Gb)* 
Run 
time(Days) 
SeqLL 
HeliScope 
Reversible 
terminator 
32
†
 28 1.2 
Pacific 
Bioscience 
PacBio 
Real time 10,000
†
 0.5
†
 80.2 
Oxford 
Nanopore 
Electronic 
Sensing 
NA NA NA 
bp, base pair; Gb, gigabase; NA, not available. 
*Reported considering the highest performances actually available for each 
platform. 
†
Average value. 
§
Paired-end sequencing. 
 
 
1.2 Next Generation Sequencing Technologies applications 
The great technological advances following the diffusion of NGS-
based approaches gave new impetus to several research topics. It is 
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important to underline that the NGS platforms are featured by a large 
flexibility. Several biological samples can be used as source and different 
kind of projects can be realized in a way and in time not easily imaginable 
before NGS revolution. This novel awareness has involved also the 
biomedical research area with the aims to markedly accelerate the search for 
genetic causes of human diseases and to answer previously difficult-to-
answer questions regarding disease pathogenesis. In recent years, several 
NGS-based approaches have been described and validated to improve the 
study of the molecular basis of human diseases with the aim to: (i) develop 
novel, sensitive, accurate, cost- and time-effective pipelines for molecular 
diagnostics; and (ii) highlight the mechanisms involved in diseases 
development to identify novel diagnostic, prognostic and therapeutic 
markers [7]. In fact, NGS technologies can be easily applied to the study of 
the human genome through a variety of approaches and until now, they have 
been successfully used to analyze target regions of the human genome, 
ranging in size from the entire exome to a restricted number of genes or a 
single amplicon [17-19]. In addition to nucleotide variants detection, NGS-
based strategies are useful also to study the DNA methylation status, both at 
single gene or at genome-wide level [20]. Finally, metagenomics has been 
really improved by NGS advent [21].This phenomenon is so diffused that is 
conceivable to suppose that novel NGS-based strategies are still developing 
and that these technologies will became even more routinely, especially for 
diagnostic purposes, considering the progressive protocol simplification, the 
operator “hand on” work reduction, and the advantages of the “bench-top” 
NGS platforms. In addition, the integration of data obtained using several 
NGS-based strategies could represent an additional advantage to better 
understand the mechanisms involved in diseases development and, in turn to 
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identify actionable target for a better patients identification, stratification 
and treatment. 
Actually, two kinds of NGS-based approaches has having a huge 
diffusion and showing their potentialities for the study of the molecular 
basis of human diseases, targeted DNA sequence capture and 
metagenomics, and will be discussed more in detail.  
 
1.3 Targeted DNA sequence capture 
Targeted DNA sequence capture is a NGS-based approach for the 
simultaneous analysis of genomic target regions selectively enriched by the 
whole DNA. 
NGS techniques allow the study of entire genomes faster and 
cheaper than conventional Sanger sequencing [22-23]. However, the entire 
sequencing of a large number of samples is not yet feasible for routine use 
due to the cost, time and infrastructures required. Thus, different approaches 
to specifically enrich target genomic regions, simultaneously allowing 
samples barcoding for sequence multiplexing, have been developed and can 
be classified in PCR-based and PCR-alternative strategies. Both of these can 
be used for NGS libraries preparation and the choose of the most 
appropriate one depend on the size of the target regions, the number of 
samples to be analyzed, the costs and time required and on the biological 
questions to be addressed (Table 3).  
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Table 3. NGS-based enrichment strategies for DNA sequence variants 
identification. 
Enrichment 
System 
DNA 
input 
Required 
Time* 
Sensitivity Specificity Max target 
size 
Long PCR 5ng/ 
amplicon 
4-5h High High Depend on 
amplicon 
length 
Multiplex 
PCR 
5ng/ 
multiplex 
3-4h High High Depend on 
amplicon 
length and 
multiplexing 
Microdroplet 
PCR 
1.5ug 48h
†
 High High Up to 20,000 
genomic loci 
WES 500ng-
2ug 
92h High >60%§ 50-75Mb§ 
Targeted 
capture 
500ng-
2ug 
92h High >60%§ Up to 50 Mb 
of custom 
regions 
WES, whole exome sequencing; Mb, megabase. 
 
 
PCR has been the most widely used pre-sequencing strategy to date, 
since it is perfectly compatible with Sanger sequencing and also with all the 
NGS instruments: at the end of the amplification, the resulting amplicons 
have NGS-platform-specific adapters ligated to their ends. This represents a 
library that is suitable for the downstream sequencing reactions [17]. Since 
barcode sequence-tags can be also added during this step, samples 
multiplexing is also allowed [24]. In general, PCR-based strategies, 
including also multiplex PCR and long range PCR, are useful to analyze one 
or a few genes [25-31]. Otherwise, since PCR amplification is too laborious 
for large scale NGS downstream applications, it risks to be a bottleneck in 
the sample preparation workflow.  
The so called “DNA sequence capture” approach is a PCR 
alternative strategy able to overcome PCR limitations and is an excellent 
way to isolate large or highly dispersed regions from a pool of DNA 
molecules [32]. Sequence capture is essentially based on hybrid capture 
19 
 
reactions for the selective enrichment of targeted genomic regions. Specific 
capture probes can be synthesized to enrich the regions of interest from the 
whole genome, thus obtaining a captured, adapted and barcoded library for 
NGS applications [18,33,34]. More in details, DNA fragments hybridize to 
the capture probes synthesized on DNA microarray glass slides in array-
based hybridization method [18], while, biotinylated DNA or RNA probes 
are used in liquid-phase hybridization. The non-targeted DNA fragments are 
washed away and the enriched DNA is recovered and used for high 
throughput sequencing (Figure 6).  
 
 
Figure 6. Schematic view of the DNA sequence capture procedure.  
 
 
An alternative technology (solution-based) is a noted example of 
enrichment system featured by selective circularization-based method which 
is a further development of the principle of selector probes used in several 
diagnostic approaches [35,36]. In brief, genomic DNA is fragmented by 
restriction enzyme digestion and circularized by hybridization to probes 
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whose ends are complementary to two non-contiguous stretches of a target 
region (Figure 7).  
 
 
Figure 7. Circularization-based procedure for selective DNA 
enrichment.  
 
 
Even if PCR-based enrichment methods have the benefit of even 
coverage and high specificity, DNA sequence capture has several 
advantages able to overcome it. Hybridization is less sensitive to 
contamination and also mismatches are less harmful. In addition, PCR 
specificity depends on reaction optimization and primer design: large 
rearrangements in genomes, for example, may be undetectable unless primer 
pairs in flanking regions. Unlike PCR, drawbacks of hybridization capture 
are the need of relatively large amount of high-quality DNA and the loss of 
target molecules during library preparation. Therefore, this approach is 
especially suitable for the study of large genomic regions, either contiguous 
or not contiguous, including the entire exome. 
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Whole exome sequencing (WES) is defined as the selective sequence 
the coding regions of a genome, to discover rare or common variants 
associated with a disorder or phenotype [37,38]. As a result, WES is an 
attractive and practical approach for the study of coding variants related to 
rare Mendelian disorders and of many disease-predisposing SNPs 
throughout the exome [39-42]. 
To reduce sequencing time and costs and avoid the drawbacks 
related to data analysis, the target enrichment of specific genomic regions of 
interest seems to be an attractive alternative. Until now, target enrichment-
based strategies, have been used for sensitive nucleotide variants 
identification [43,44], validation of novel diagnostic tools [45-47] and drug 
resistance/sensitivity profiling [48-50]. This method is useful for the study 
of complex families with different genotype/phenotype correlation and to 
identify all the at risk subjects [51].  
Considering all the above, and also that target enrichment 
technologies are easy to use, they appear really suitable for the study of the 
molecular basis of genetic diseases, both for research and diagnostic 
purposes. 
 
1.3.1 Inherited cardiomiopathies 
Inherited cardiomyopathies are a group of heterogeneous genetic 
diseases usually classified according to functional and morphology 
abnormalities of the cardiac muscle. It includes hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic 
right ventricular cardiomyopathy (ARVC), left ventricular noncompaction 
(LVNC), and restrictive cardiomyopathy (RCM). In addition, another group 
of inherited cardiomyopathies is featured by a primary involvement of 
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cardiac electric transmission (channelopathies) and includes long QT 
syndrome (LQTS), short QT syndrome (SQTS), Brugada syndrome, and 
catecholaminergic polymorphic ventricular tachycardia (CPVT). All these 
diseases are featured by a high clinical and genetic heterogeneity [52].  
Clinical presentation ranges from asymptomatic to severe rapidly 
worsening forms and the same symptoms can be the expression of different 
diseases. The age of onset is also extremely variable: sometimes an 
inherited cardiac disease is diagnosed before birth, while other subjects can 
show clinical signs later in the adulthood [52]. Most relevant, all of these 
diseases can predispose to the development of malignant arrhythmias, heart 
failure and sudden cardiac death (SCD). It has been estimated that the 
majority of SCD in young individuals can be related to the presence of one 
of the above mentioned diseases [53]. Therefore, the correct identification 
of the molecular alterations responsible for inherited cardiomyopathies is 
crucial for the correct patient’s management and for the identification of all 
the at risk subjects within the affected families. 
The cardiomyopathies’ clinical variability is reflected in the 
heterogeneity of their genetic basis. To date, tens of genes, showing 
different mechanisms of inheritance and incomplete penetrance, have been 
related to the onset of each inherited cardiomyopathy. However, they 
explain only a variable proportion of all cases suggesting the existence of 
other, still unknown disease-causative genes [52]. In addition, the highly 
variable phenotipic expression, also in the presence of the same causative 
mutation and in the same family, has strongly suggested a role for additional 
inherited variants, in the same gene or in independently inherited genes, able 
to act as phenotype-modifiers. Finally, molecular variants in the same gene 
have been related to different cardiomyopathies.  
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Taken together, all the above mentioned issues explain the 
difficulties in the correct molecular diagnosis of these overlapping diseases. 
Therefore, NGS-based approaches, enabling the simultaneous analysis of 
large number of genes, promise to overcome these limitations. Increasing 
evidences are assessing the potentialities of NGS-based approaches for the 
study of inherited cardiomyopathies [52]. van de Meerakker et al identified, 
in a DCM family, a novel mutation in the alpha-tropomyosin gene through 
the targeted enrichment of a panel of 23 candidate genes (array-based 
enrichment) [54]. In another study, the custom enrichment of 16 genes was 
able to identify a compound heterozygosis in an infant affected by LVNC, 
confirming the potential of NGS as fast diagnostic tool [55]. Similar 
approaches have been used in different patient settings showing their 
reliability in terms of accuracy and sensitivity also for diagnostic pulposes 
[56-62] Finally, post-mortem WES was able to identify the causative 
mutation in a young women death for SCD [63]. Taken all together, these 
findings assess the feasibility of NGS for the study of complex inherited 
diseases, such as inherited cardiomyopathies and suggest their use as routine 
diagnostic procedure in a molecular biology laboratory. 
 
1.4 Metagenomics 
Metagenomics is defined as the field of molecular research that 
studies the complexity of microbiomes, i.e. the entire collection of all the 
genomic elements of a specific community of microrganisms, including 
bacteria, archaea, viruses, and some unicellular eukaryotes, living in a 
specific environment (microbiota). 
In the last few years, metagenomics literature has grown 
exponentially, essentially due to technological improvements related to the 
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introduction of NGS. This has, in turn, greatly improved our understanding 
about the role of human microbiota in the healthy status and its possible 
implications in diseases pathogenesis [64]. 
If we consider the human body as an environment, the human 
microbiota is the entire collection of microorganisms living on the surface 
and inside our body (Table 4) [65-68].  
 
Table 4. Human microbiota composition across the five most 
extensively studied body sites. Interestingly, the oral and gut microbiota 
have the highest microbial diversity, while the urogenital tract has the 
smallest bacterial diversity [from 64]. 
 Human microbiota 
(10 times more microbial than human cells: 10
14
 vs 
10
13
) 
 
Human Microbial 
Habitats 
Most represented Phyla and their relative 
abundance (%) 
Number of 
species 
Oral cavity
 Firmicutes (36.7), Bacteroidetes (17.3), 
Proteobacteria (17.1), Actinobacteria (11.9), 
Fusobacteria (5.2)  
>500 
Skin
 Actinobacteria (52), Firmicutes (24.4), 
Proteobacteria (16.5), Bacteroidetes (6.3) 
~300 
Airways
 Actinobacteria (55), Firmicutes (15), 
Proteobacteria (8), Bacteroidetes (3) 
>500 
Gut
 Firmicutes (38.8), Bacteroidetes (27.8), 
Actinobacteria (8.2), Proteobacteria (2.1) 
>1,000 
Urogenital tract
a Firmicutes (83), Bacteroidetes (3), 
Actinobacteria (3) 
~150 
a
mainly female. 
 
 
These communities are required for human physiology, immune 
system development, digestion and detoxification reactions [60,70]. In this 
view, humans can be defined as “superorganisms” made of two genomes, 
one inherited from parents and the other acquired, i.e., the microbiome [71]. 
Differently from the inherited genome, which is almost stable during 
lifetime, the microbiome is extremely dynamic and influenced by age, diet, 
hormonal cycles, travel, therapies, and illness [72-77]. 
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Most of the human adult microbiota lives in the gut. Only in the 
human colon microbial cell density exceed 10
11
 cells/g contents, being 
equivalent to 1-2 kg of body weight [78]. In addition, it has been estimated 
that the human gut microbiome accounts for more than 5 million different 
genes [79]. Even if over 1,000 different species colonize the human gut 
[21], they belong to a small number of phyla: Firmicutes, Bacteroidetes and 
Actinobacteria, followed by the less represented Proteobacteria, 
Fusobacteria, Cyanobacteria and Verrucomicrobia [70]. To date, a number 
of functions have been associated to the gut microbiome, including 
polysaccharide digestion, immune system development, defense against 
infections, synthesis of vitamins, fat storage, angiogenesis regulation, and 
behavior development [69,70,80,81]. Therefore, it is conceivable to suppose 
that alterations of the human gut microbiome can play a role in disease 
development and more our understanding on its role will grow up, more it 
will became possible to use the human microbiome for diagnostic purposes 
or as target for novel therapies.  
All the above, explain the boom of metagenomics worlwide. NGS 
plays its role in this scenario, since it allows the qualitative and quantitative 
analysis of a specific microbiome without selection biases and constraints 
associated with cultivation methods. Different NGS-based strategies can be 
used for metagenomic purposes, as shown in Figure 8.  
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Figure 8. Next Generation sequencing-based approaches for 
metagenomics. Starting from an environmental sample of interest (1), total 
DNA and/or RNA are extracted (2). Three different sample preparation 
strategies can be used depending on the project aims: 16s rRNA 
Sequencing, Shotgun Sequencing, and Metatranscriptomics (3). Usually, the 
16S rRNA procedure allows sample multiplexing while a higher coverage is 
required for the others. After sequencing (4), specific bioinformatic 
pipelines are used for data analysis (5) [from 64]. 
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Shotgun approaches allow a comprehensive view of entire microbial 
communities both at DNA or RNA level, with taxonomic assignment up to 
the species. However, they still have technical limitations, most of which 
related to sequence data analysis. Therefore, the most used approach is the 
targeted resequencing of specific sequence tags useful for phylogenetic 
purposes, like the bacterial 16S rRNA gene. The latter gene has a peculiar 
structure characterized by hypervariable regions spaced by ultra-conserved 
regions [82]. Universal primers which anneal on the conserved regions can 
be used to amplify, in a single PCR reaction, virtually all the bacteria 
present in a target environment, and to unequivocally identify them at the 
end of sequencing [83]. 
This approach has been successfully used to analyze the microbial 
community richness of the human gut microbiome and its relationship with 
specific diseases, such as obesity and immune-related and inflammatory 
diseases [84-93]. It is now well known that the gut microbiome of obese 
subjects differ from that of not obese and that such differences could play a 
role in altering gut permeability and induce inflammatory reactions [91-93]. 
Similar mechanisms seems to be applicable to an increasing number of 
intestinal and extra-intestinal diseases, including inflammatory bowel 
diseases and celiac disease [84-87].  
 
1.4.1 Gut microbiome and inflammatory bowel diseases 
Inflammatory bowel disease (IBD) are chronic inflammatory 
disorders of the gastrointestinal tract with increasing worldwide incidence 
[94]. IBD clinical features are severe, including diarrhea, weight loss and 
debilitating abdominal pain, and result in substantial morbidity and 
impairment in quality life [95]. IBD also increase the risk for colon cancer 
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development [96]. The affected intestinal areas are usually characterized by 
transmural inflammation associated to lymphoid hyperplasia, submucosal 
edema, ulcerative lesions and fibrosis which can be assessed by 
colonoscopy [97]. The two main forms of these disorders are Crohn disease 
(CD) and ulcerative colitis (UC). IBD causes are still unclear. Even if host 
genetics play a key role, mostly in CD than in UC onset [98], environmental 
factors are also involved [99]. Numerous evidences emphasize the role of 
gut microbiome in triggering and perpetuating typical IBD chronic 
inflammation. The most widely currently accepted hypothesis on IBD 
pathogenesis is that, in genetically predisposed subject, an altered host 
immune response against luminal agents, such as the gut microbiota, could 
result in the IBD chronic inflammation [97,100]. 
It has been established that microbes rapidly colonizes the gut after 
birth [101] and this process is influenced by different factors, such as the 
heredity of the mother, the immediate living environment, the feeding 
practices, microbial infections, and the host’s genetics [102]. As discussed 
above, this mutual relationship between the human host and its microbiota 
seems required for healthy status acquisition and maintenance.  
Several studies have identified significant alterations in the gut 
microbiota composition of IBD patients with respect to healthy individuals 
[103,104]. Therefore, there is a growing interest in understanding whether 
interactions between intestinal microbes and innate immunity could 
influence IBD expression and act as triggers of the inflammation, since this 
could open the way to novel diagnostic and therapeutic opportunities. In 
addition, since nutritional therapy is effective in pediatric Crohn disease, it 
has been suggested that it may induce its beneficial effects by modifying the 
microbiome composition [105]. 
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1.4.2 Gut microbiome and celiac disease 
Celiac disease (CD) is a chronic, multi-factorial, inflammatory 
disorder of the small intestine that involves interactions between genetic and 
environmental factors [106]. In genetically susceptible individuals (HLA-
DQ2/DQ8 carriers) ingestion of gluten leads to an abnormal intestinal 
immune response involving both adaptive and innate immunity, which is 
characterized by failure to establish and/or maintain tolerance to dietary 
peptides in wheat, barley, and rye (particularly to wheat gliadin) [107]. This 
abnormal immune activity damages the small intestine, which typically 
shows villous atrophy, crypt hyperplasia, and an increased number of 
lymphocytes within both the epithelium and the lamina propria [108]. 
However, more recent studies have challenged the gluten-hypersensitivity 
dogma and suggest that exposure to gluten may not be the only factor 
contributing to the onset of CD [109,110]. Indeed, traditional pathogenic 
mechanisms of gluten hypersensitivity do not explain why: i) the frequency 
of DQ2/DQ8 molecules in the general population is about 30%, but only 1to 
3% of individuals develop CD [106]; ii) CD is increasingly diagnosed in 
adulthood, many years after introduction of gluten in the diet [111]; iii) the 
prevalence of CD prevalence is rapidly increasing in the western world 
(although consumption of gliadin-containing food has not increased) [112]. 
All these observations support the idea that other environmental factors, as 
the gut microbiome, could play a role in CD pathogenesis.  
A number of studies have identified significant alterations in the 
composition of the gut microbiota in CD patients with respect to healthy 
individuals [113,114]. As for other diseases, also in this case the 
relationship between intestinal microbes and innate immunity through their 
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role in promoting inflammation and impairing mucosal barrier functions 
could clarify CD pathogenesis and give novel opportunities for patients 
care. 
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II. AIMS  
 
The aim of this PhD project was to use next generation sequencing 
(NGS)-based strategies to study the molecular basis of human diseases with 
the specific aims to: i) increase diagnostic sensitivity, respect to commonly 
used techniques; ii) identify novel disease-causing genes; iii) identify 
phenotype modifier genes able to justify the heterogeneity of clinical signs; 
and iv) clarify pathogenetic mechanisms involved in disease development. 
To do these, we used two different NGS-based approaches: targeted DNA 
sequence capture and metagenomics. 
Targeted DNA sequence capture was used to assess the feasibility of 
this approach for the study of a large panel of candidate target genes 
possibly related to complex (highly heterogeneous from both molecular and 
clinical points of view) inherited diseases. We studied, as model disease, the 
inherited cardiomyopathies. Particularly, we carefully evaluated results 
reliability to assess methods portability into routine diagnostic settings. In 
addition, we evaluated the feasibility of pooling together barcoded DNA 
samples from various patients in order to reduce the cost and time of the 
procedure. 
Metagenomics, through the 16S bacterial rRNA analysis, was used 
to verify the presence of a specific dysbiosis into the composition of human 
gut microbiome in association to specific diseases. In this case, we used as 
model two inflammatory diseases: Crohn and celiac disease. In particular, in 
Crohn disease we aimed to assess the effects of nutritional therapy on the 
microbiome composition. 
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III. MATERIALS AND METHODS 
 
3.1 Patients selection and biological samples collection 
 
3.1.1 Targeted DNA Sequence Capture 
Three unrelated individuals with a clinical diagnosis of hypertrophic 
cardiomyopathy (HCM) were selected for the present project with the aim to 
validate a targeted DNA sequence capture approaches for the study of 
inherited cardiomyopathies. HCM was defined as unexplained left or left 
and right ventricular hypertrophy in the absence of any potential cause of 
cardiac hypertrophy. It was diagnosed by echocardiographic evidence of 
increased wall thickness, two standard deviations or more above the upper 
reference limit of healthy individuals matched for age, sex, and body surface 
area. Maximal ventricular wall thickness (MWT) was defined as the greatest 
thickness in the various segments and measured as absolute value and as z-
score for age and body surface area; z-score reference value < +2 [115]. 
Normal reference ranges of specific electrocardiographic (ECG) features 
were: PR: 0.12-0.20 sec; QRS: 0.06-0.10 sec; QTc: < 440 msec in men, < 
460 msec in women.  
Patient 1 was diagnosed with unexplained left ventricular 
hypertrophy (LVH) and cleft mitral valve during intrauterine life. HCM 
with asymmetrical LVH was confirmed at birth (MWT anterior 
interventricular [IV] septum was 8 mm at; z-score +7). This patient was 
followed-up at the Cardiomyopathy Clinic of the Monaldi Hospital (Naples, 
Italy) with regular ECG and echocardiographic evaluations. Verapamil 
therapy was started and the left ventricular wall thickness progressively 
normalized during childhood. No significant progression of LVH was seen 
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at follow-up. This is similar to a previous report [116]. At the last clinical 
evaluation, at 15 years of age, she showed the mitral cleft with concomitant 
mild-to-moderate regurgitation; her septal thickness was nearly normal 
(MWT at anterior IV septum was 12 mm; z-score +3.1). Patient 2 (now 8 
years old) was diagnosed at birth with non-obstructive HCM and multiple 
septal ventricular defects (MWT at anterior IV septum at 4 months age was 
8.3 mm; z-score +6.1). During follow-up, in the absence of cardiological 
therapy, LVH did not progress and all ventricular septal defects, except one, 
closed [116]. Her ECG showed signs of LVH and a long QTc (490 msec), 
which was considered “a secondary effect” of the cardiac hypertrophy. At 
last follow-up, MWT at the anterior IV septum was 8 mm (z-score +1.4). 
Patient 3 was diagnosed at birth with a valvular pulmonary stenosis, and 
underwent a surgical valvulotomy at 14 years of age. He was diagnosed 
with diabetes mellitus and polycythemia at 44 years of age. One year later, 
he had the first episode of atrial fibrillation/flutter. He also showed a first-
degree atrioventricular block, an incomplete right bundle branch block 
(QRS 110 msec), and a long QTc (QT 495 msec). Echocardiography 
showed non obstructive HCM (MWT at anterior IV was 15 mm; z-score 
+4.4). The patient and his younger daughter also suffer from minor 
depressive disorders. Patient 3 underwent biochemical investigation and a 
muscle biopsy to exclude that LVH was of a secondary nature (biochemical 
evaluation: normal lactate/pyruvate ratio; normal CK, AST, ALT; muscle 
biopsy: negative COX and SDH fibers, normal mitochondria, no inclusion 
bodies). During follow-up, recurrent episodes of atrial fibrillation/flutter and 
a progressive end-stage evolution (“burn out”) were observed; thus the 
patient underwent orthotropic heart transplant in 2011 at 51 years of age 
(MWT at anterior IV was 17 mm before heart transplantation; z-score +5.8). 
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Two of these patients (1 and 2) had previously been evaluated by using a 
DHPLC/Sanger test to search for causative mutations within the exons of 8 
sarcomeric genes: MYH7, MYBPBC3, TNNI3, TNNT2, TPM1, ACTC, MYL2 
and MYL3 [115].
 
The molecular analysis was extended also to the patient’s 
relatives in order to study mutations segregation in each family. We 
obtained informed consent from each patient and family member, according 
to the procedures of the institutional review boards of the participating 
institutions.  
Blood samples were obtained from each subject. Total DNA was 
isolated from peripheral blood using the Nucleon BACC3 Genomic DNA 
Extraction Kit (GE Healthcare, Life Sciences) according to the 
manufacturer’s instructions. Then, samples quantification was done through 
the NanoDrop 2000c Spectrophotometer (Thermo Scientific).  
 
3.1.2 Metagenomics 
With regard the gut microbiome characterization of Crohn disease, 
two child where enrolled for the project. In particular, one child was 
affected by Crohn disease and underwent nutritional therapy, the other was 
a sex- and age-matched not affected subject. The Crohn disease patient was 
a 14-year-old boy diagnosed with active Crohn disease (Pediatric Crohn’s 
Disease Activity Index, PCDAI=50). After colon endoscopy, he underwent 
nutritional therapy consisting of a daily powder constituted by proteins, 
antioxidants and anti-inflammatory fats (Alicalm formula, Nutricia 
Advanced Medical Nutrition) for 8 weeks. After this time, a clinical re-
evaluation revealed disease remission (PCDAI= 0). Endoscopic ileum 
mucosal samples at diagnosis (BT-patient) and after therapy (AT-patient) 
were collected for DNA extraction. An ileum tissue sample was obtained 
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also from a 15-year-old boy affected by a gut polyp and without familiarity 
for Crohn disease.  
To study the mucosal gut microbiome of celiac disease (CD), 15 
active CD patients, 10 clinical controls and 6 at gluten free diet (GFD) CD 
patients were recruited among patients attending the Departments of 
Gastroenterology of the Universities of Salerno and of Roma-Tor Vergata, 
Italy. The exclusion criteria for enrolment were: any known food intolerance 
apart from gluten, IgA deficiency, treatment with antibiotics, proton pomp 
inhibitors, antiviral or corticosteroids, or assumption of probiotics in the 2 
months before the sampling time. Duodenal biopsies from all the enrolled 
individuals were collected during diagnostic endoscopy procedures.  
Total DNA was extracted from all collected biopsies (3 mg/sample, 
duodenum for CD and ileum for Crohn disease respectively) using the 
QIAamp DNA mini Kit (Qiagen,Venlo, Netherlands), following the 
manufacturer’s instructions. 
 
3.2 NGS Library Preparation 
 
3.2.1 Targeted DNA Sequence Capture 
Gene selection and microarray design. A list of target candidate 
genes was produced by selecting all the genes related to cardiomyopathy 
onset and the genes coding for ionic channels, membrane receptors, growth 
factors and inflammatory and transcriptional factors [117-122]. Thus, 202 
genes of interest were identified (Appendix 1), and a list with their refseq 
IDs was generated. Starting from this list, 2,250 genomic targets were 
selected, each corresponding to one or more exons, plus a flanking region of 
500 bp at the 5’ and 3’ ends of each exon. These genomic coordinates, 
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including chromosome start and stop positions, were used to define unique 
probes for the final set of 4,790 probed regions (one or more for each target) 
for a total of about 3.9x10
6
 bp. The microarray was provided by Roche 
Nimblegen Inc. (Madison, WI, 454 Optimized Sequence Capture 385K 
Array). Probe uniqueness was assessed by comparing the probe sequence to 
the genome [123]. 
Enrichment of target sequences. The selected regions were captured 
according to the manufacturers’ protocols using the NimbleGen 
Hybridization System (Nimblegen and Roche, NimbleGen Arrays User’s 
Guide: Sequence Capture Array Delivery v3.2) [18]. The procedures is 
based on four main steps: i) preparation of a library of adapted DNA 
fragments; ii) library hybridization on the custom capture array; iii) enriched 
library fragments recovery; and iv) enrichment assessment. In brief, 21 µg 
of genomic DNA from each sample were sheared into small fragments 
(range size: 300-500 bp) through nebulization. After fragments ends 
polishing and purification (AMPure Beads, Agencourt), specific adapters 
(Adaptor A and B) were ligated to each fragments. After quality (DNA 
chip1000, BioAnalyzer, Agilent) and quantity assessment (NanoDrop, 
Thermo Scientific), each library has been amplified and hybridazed on the 
custom array for 72h. After incubation, stringent washes were performed to 
remove the unbound fragments, while the enriched fragments were eluted 
and amplified. Sample enrichment was evaluated according to the 
manufacturer’s instructions, i.e. by measuring, through quantitative PCR 
analysis, the relative fold-enrichment of 4 control loci present in each 
capture array. The analysis was carried out on a LightCycler 480 real time 
PCR system (Roche). 
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3.2.2 Metagenomics 
An aliquot of the tissue DNA was used for PCR amplification and 
sequencing of bacterial 16S rRNA gene. To deeply investigate the bacterial 
composition of gut mucosal samples, a 548 bp amplicon, spanning from V4 
to V6 variable regions of the 16S rRNA gene, was amplified using the 519F 
and the 1067R primers [124]. Both primers were modified to obtain fusion 
primers so that each one contained at the 5’ end a universal 454 adaptor 
(adaptor A for forward primer and adaptor B for the reverse) and a specific 
10 nucleotide tag/sample (Table 5). 
 
Table 5. List of the primers’ sequences used to amplify, by NGS 
methodology, the bacterial 16S V4-V6 region. For each couple the 
sequences are reported from 5’ to 3’, both on forward and reverse primers. 
Each primer is a fusion primer resulting from the following sequences (from 
left to right): i) the 454-Roche adaptor sequences (adaptors A and B) 
required for emulsion amplification and sequencing reactions (upper case 
characters); ii) the sample-specific 10 nucleotide tag sequences (MID 1-10) 
required to univocally tag each individual subject (underlined characters); 
iii) the primers’ template-specific sequences (bold characters). 
16S Primers for whole microbiota amplification 
F (5’-3’) R (5’-3’) 
Adaptor A                                                              
MID (1-10)             Template Specific Primer 
 Adaptor B                                                        
MID (1-10)          Template Specific Primer 
CGTATCGCCTCCCTCGCGCCATCAG-
ACGAGTGCGT-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
ACGAGTGCGT-TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
ACGCTCGACA-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
ACGCTCGACA-TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
AGACGCACTC-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
AGACGCACTC-TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
AGCACTGTAG-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
AGCACTGTAG-TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
ATCAGACACG-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
ATCAGACACG-TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
ATATCGCGAG-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
ATATCGCGAG-TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
CGTGTCTCTA-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
CGTGTCTCTA- TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
CTCGCGTGTC-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
CTCGCGTGTC- TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
TAGTATCAGC-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
TAGTATCAGC-TGACGACAGCCATGC 
CGTATCGCCTCCCTCGCGCCATCAG-
TCTCTATGCG-CAGCAGCCGCGGTAATAC 
CTATGCGCCTTGCCAGCCCGCTCAG-
TCTCTATGCG- TGACGACAGCCATGC 
F: forward; R:reverse. 
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PCR reactions were carried out using 25 µl of H2O, 20 µl of 2.5X 
HotMaster PCR mix (Eppendorf), 1.5 µl of each primer 10 µM and 60 ng of 
DNA. The amplifications were performed on a DNA ENGINE Chassis 
(Biorad) at the following conditions: 2 min at 94°C, 30 cycles of 94°C for 
40 s, 50°C for 40 s, and 65°C for 40 s, and a final extension of 70°C for 7 
min. After visualization by agarose gel electrophoresis, each PCR products 
was individually purified using magnetic purification beads (AMPure 
Beads, Agencourt), assessed for quality on a Bioanalyzer 2100 (DNA 1000 
chip, Agilent) and quantified using the Quant-it PicoGreen dsDNA kit 
(Invitrogen). Equimolar amounts of each amplicon were pooled together to 
obtain multiple amplicon libraries, each containing a total of 5 mixed 
subjects. 
 
3.3 NGS Library Amplification and sequencing 
Both the NGS-based approaches used in the present project were 
carried out using the GS FLX System (454 Roche). Therefore, the obtained 
DNA libraries were amplified through emPCR and sequenced using the 
pyrosequencing chemistry, according to the manufacturer’s specifications 
[10]. 
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3.4 Bioinformatics 
 
3.4.1 Targeted DNA Sequence Capture 
Read mapping and variant detection. The obtained sequencing reads 
were mapped by using the GS Reference Mapper software package (454 
Roche, version 2.6), with the default parameters. Variants were identified by 
comparing assembled vs reference genomic sequence (hg19, 
http://genome.ucsc.edu/cgi-bin/hgGateway). The procedure produces a list 
of high confidence nucleotide differences (HCDiffs), as well as a larger list 
of all nucleotide differences (AllDiffs), identified by a less stringent 
approach. The GS Reference Mapper uses a combination of flow signal and 
quality score information together with the type of nucleotide change to 
determine if a variant is to be treated as a high-confidence variant. The 
strategy used to select HCDiffs is based on the following criteria: 1) there 
must be at least 3 non-duplicate reads with the difference, with at least 5 
bases on both sides of the difference, and a few other isolated sequence 
differences in the read; 2) there must be both forward and reverse reads 
showing the difference, unless there are at least 7 reads with quality scores 
over 20 (or 30 if the difference involves a homopolymer of 5 nt or more); 3) 
not all overcalls/undercalls are reported as insertions/deletions, but only 
those where the difference is the consensus of the sequenced reads. The 
AllDiff strategy is less stringent and requires at least 2 non-duplicate reads, 
without restrictions in terms of forward/reverse strands. To facilitate 
downstream analyses, the complete list of variants (AllDiffs/HCDiffs), 
together with relevant information concerning target coverage, were 
imported in a relational database based on PostgreSQL 
(http://www.postgresql.org). 
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Genotype calling and statistical analyses. For each candidate 
polymorphic site, the genotype was assigned according to a procedure for 
evaluation of statistical significance of deviations from the predicted 
distribution of reference-supporting/alternative-supporting read frequency in 
the case of alternative-homozygous (a/a), heterozygous (r/a) and reference-
homozygous (r/r) subjects. The procedure was based on a binomial exact 
test where the probability (P) of producing the observed frequencies is 
calculated starting from three alternative hypotheses [125], corresponding to 
a ratio of 0.99, 0.5 and 0.01 for a/a, r/a and r/r respectively, as one would 
expect for a sequencing error rate of 0.01 [126]. The hypothesis with the 
highest P-value was taken as the result; a quality score was calculated as the 
logarithm with base 10 of the ratio between the highest and second best P-
value. P-values were calculated by using the binom.test function from the R 
statistical software environment (http://www.r-project.org/). 
Assessment of the NGS methodology. The sensitivity and specificity 
of the described NGS-based procedure was assessed by evaluating its ability 
to identify all base changes present in a subset of eight genes, previously 
associated with HCM[115]. This test was carried out on two patients in 
which the same eight genes had previously been analyzed[115], by using a 
combination of DHPLC and Sanger sequencing. For both procedures, the 
analysis was targeted to 128 exons extended by 60 flanking bases on each 
side, for a total of 34,067 bp (Table 6).  
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Table 6. Summary of the features of the genomic regions analyzed 
by both NGS and DHPLC/Sanger methods. These regions were used 
to evaluate NGS reliability with best estimate method. 
  NGS DHPLC/Sanger 
  Target 
Target exons 128 128 
Target bases  34,067 34,067 
  Experimental Design 
Segments 2245 125 
Bases (n) 3,897,552 38,013 
Targets in design 128 128(54*) 
Target bases in design 34,067 29,014 
*number of targets partially covered. 
 
 
We evaluated both the NGS-based and DHPLC/Sanger procedures 
by testing their ability to correctly detect all base changes present in the 
patients’ sequence. No technique clearly better than the two procedures 
being tested is yet available to be used as a “gold standard”. Therefore, for 
each patient a “best estimate” sequence was obtained by combining and 
reviewing for each position all the available experimental data. Specifically, 
when automated sequencing data univocally identified a nucleotide by all 
methods, it was accepted as such; in all other cases comparative analysis of 
the results was carried out by hand. When data from Sanger and NGS 
sequencing were both available, but divergent, the results could often be 
reconciled by visual inspection of electropherograms (Sanger) and multiple 
alignment of NGS reads, and taking into account the most common 
interpretation mistakes, namely small peaks, too few or conflicting reads 
and so on. In these cases the resulting nucleotide was accepted and included 
in the best estimate sequence; when base and genotype assignment could not 
be unambiguously obtained, the position was not accepted and therefore 
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removed from the “best estimate” sequence. This effort produced a 
sequence that best fits the deepest level of analysis performed, and that was 
used as a reference to assess the sensitivity and specificity of the NGS and 
the DHPLC/Sanger procedures, by counting as true positive (TP), true 
negative (TN), false positive (FP) or false negative (FN) the results 
available from the each of the two procedures, taken independently. 
Sensitivity and specificity were then calculated according to the 
conventional formulas: Sensitivity = TP/(TP+FN); Specificity = 
TN/(TN+FP). Confidence intervals for sensitivity and specificity were 
estimated by using the Pearson-Klopper method, and the R statistical 
software environment. 
The aim of the DHPLC approach we used was to identify rare exon 
sequence changes; therefore some variants identified by NGS were difficult 
to detect or undetectable as they are located: a) close to the ends of the 
amplicons analyzed by DHPLC; b) homozygous; or c) within untranslated 
sequences. To better assess DHPLC sensitivity making the results of 
calculations comparable to those of other reports, these calculations were 
repeated by excluding these variants, as reported under Results. 
Variant annotation. The potential consequence of nucleotide 
substitutions, insertions and deletions on transcripts and other functional 
elements was examined using the “Variant Effect Predictor” tool [127], 
version 2.5, and the release 67 (May 2012) of transcripts and regulatory 
regions annotated in Ensembl (http://www.ensembl.org). The same tool was 
used to map variant loci to previously described SNPs. The allele frequency 
in each of the 1,000 Genomes super-populations (EUR, which is the 
population closest to our three subjects, ASN, AFR and AMR) was 
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annotated, when available, by using a custom developed script based on 
Ensembl's perl API (http://www.ensembl.org) [128]. 
 
3.4.2 Metagenomics 
16S rRNA barcoded amplicon sequences were analyzed using 
QIIME v. 1.8.0
 
[129]. Sequences were quality filtered and demultiplexed 
using default QIIME parameters. The filtered reads were assigned to 
operational taxonomic units (OTUs) using an open-reference OTU picking 
approach on the basis of sequence similarity using UCLUST [130] against 
the Greengenes database (v. 13_5) [131] at 97% identity. A representative 
set of sequences was taken for each OTU and taxonomic classification was 
performed with the Ribosomal Database Project (RDP) classifier 2.2 [132]. 
Next, the representative sequences were aligned using PyNAST [133] to the 
Greengenes Core reference alignment [134] and a phylogenetic tree was 
built using FastTree [135]. The phylogenetic tree was used for downstream 
phylogenetic community analyses. Community diversity analyses at a 
rarefaction depth of 854 sequences/sample were performed using QIIME 
related scripts. Principal coordinates analyses (PCoA) were generated from 
UniFrac weighted and unweighted distance matrices [136]. 
In order to assess whether specific taxa were significantly 
differentially abundant across study groups, we used the analysis of variance 
(ANOVA) test together with a Bonferroni correction using QIIME scripts. 
OTUs with p-value ≤ 0.05 after Bonferroni adjustment were considered 
statistically significant. To compare the alpha diversity across sample 
groups, a non-parametric two sample t-test was run using 999 Monte Carlo 
permutations to calculate the p-values. Analysis of Similarity Statistics 
(ANOSIM)
 
[137] and non-parametric multivariate ANOVA (Adonis) [138] 
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using Unifrac distance matrices were used to test the significance of 
differences in the beta diversity. 
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IV. RESULTS 
 
 
4.1 Targeted DNA Sequence Capture 
NGS analysis. Each of the three selected patients and their genomic 
pool DNA sample were separately analyzed as described under Materials 
and Methods. Target DNA enrichment of the 202 selected genes was carried 
out using a array-based hybridization method. Capture efficiency in the 
three patients, as assessed by quantitative PCR analysis, typically ranges 
between 280 and 330 fold, well above the suggested 200 fold threshold 
indicative of an acceptable capture prior to sequencing. The pooled DNA 
sample yielded a 390-fold enrichment. The amount of captured DNA was 
measured by spectrophotometry, and the average yield was 10 μg per 
sample. Two sequencing runs were performed with each sample loaded in 
one large PicoTiterPlate region. This procedure yielded on average 203 
Mb/sample, with a number of sequencing reads around 650,000/sample with 
a very similar read length of ~330 bp (Table 7). The same analytic strategy 
was used for the DNA pool. The pooled sample was sequenced in duplicate 
on a PicoTiterPlate in a single run. The procedure yielded more than 307 
Mb, being equivalent to 1,067,389 sequencing reads with an average size of 
298 bp (Table 7). For all samples, over 90% of the reads were 
unambiguously mapped on the human genome reference sequence, while a 
fraction ranging between 72.8% and 76.5% of all reads fell within the 
targeted regions. Overall, this corresponds to an average enrichment of the 
targeted DNA of 595-fold, calculated as the ratio between the fraction of 
reads mapped on the targets and the fraction of the human genome 
represented by them. With this approach, a variable length of DNA 
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sequence, adjacent to both ends of the targets, was also usually determined, 
in addition to targeted sequences. Average sequencing depth within the 
target area ranged from 32.8x to 36.1x for the three patients (Table 7), while 
the number of “covered” targets varies depending on the depth that is 
defined as “acceptable”, and that is used as a threshold (Figure 9). If a 
minimum accepted depth of 10x is chosen, at least 91.8% of the targeted 
bases were covered for all patients (Figure 9A). These values are similar to, 
or even higher than, the coverage reported in other studies aimed at 
detecting sequence variations in inherited diseases [139-144]. Most low 
depth or uncovered bases were located within a small number of targets, 
ranging between 32 and 63 for the three patients. These targets were 
completely unsequenced, probably because of low efficiency capture in the 
enrichment procedure (Figure 9B). The average sequencing depth of the 
pooled sample was 45.4x, as expected from duplicate analysis (Table 7). 
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Table 7. Overview of the entire sequencing and annotation procedure. 
The table shows the results obtained for patients P1, P2, P3 and the pool 
containing DNA from the three patients plus a control. The target overall 
gene regions (4Mb) include the 202 genes selected in this study (see 
Materials and Methods and Appendix 1). 
  P1 P2 P3 Pool 
qPCR enrichment 
(fold) 
319 333 288 390 
Total Sequenced 
bases (bp) 
197,796,849 215,720,477 197,375,419 307,280,122 
Total Sequenced 
reads (n) 
629,332 687,163 627,170 1,067,389 
Average reads 
length (bp) 
328.41 325.54 329.43 298.02 
Reads mapped on 
genome (n/%) 
584,128/92.8 646,491/94.1 582,455/92.9 1,002,244/93.9 
Reads mapped on 
targets (n/%) 
458,343/72.8 525,851/76.5 474,050/75.6 793,459/74.3 
Target DNA 
enrichment (fold) 
578 607 600 579 
Average depth 
(fold ± s.d.) 
32.8 ± 16.3 34.2 ± 17.3 36.1 ± 18.9 45.4± 21.4 
Target coverage 
with depth >0 (%) 
99 99 99 99 
Target coverage 
with depth >8 (%) 
93 94 93 96 
Target coverage 
with depth >15 
(%) 
84 86 85 91 
Total identified bp 
differences 
(AllDiffs) 
20,500 19,654 20,904 30,580 
High Confidence 
bp differences 
(HCDiffs) 
6,894 6,157 6,371 9,115 
Variants in final 
set (all/novel) 
3,350/1,456 2,721/985 2,902/1,204 - 
qPCR, quantitative PCR analysis; P1, P2, P3, patients; HC, high confidence; 
n, absolute number; s.d., standard deviation. 
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Figure 9. Coverage of targeted bases and regions. A) Relative coverage 
of bases contained within targeted regions is shown for each of the three 
individuals. B) Number of target regions vs average coverage depth, right 
cumulated. The color code is referred to each of the three patients that show 
a very similar behavior. 
 
 
Variant detection, genotype calling and variant annotation: 
prioritization pipeline. Candidate variants were detected by using the GS 
Reference Mapper software. As reported in Table 7, of the many 
hypothetical variants reported in the AllDiff list, 6,894, 6,157 and 6,371 
were selected by the HCDiff selection procedure in patients 1, 2 and 3 
respectively. For each HCDiff variant, the genotype was defined according 
to a significance evaluation test (see Materials and Methods). This test was 
used to identify additional potential detection errors, i.e; r/r loci that 
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erroneously passed the HCDiff filter. In fact, a small number of variant loci 
(92, 69, 77 respectively) are better designated as reference-homozygous (r/r) 
(Table 8).  
 
 
Table 8. Genotype assignment. Genotype was assigned for the various 
high confidence (HC) bp differences (Diffs), based on binomial exact test 
and reported separately for each patient. 
Subject HCDiffs HCDiffs r/r
* 
HCDiffs 
r/a† 
HCDiffs 
a/a‡ 
P1 6,894 92 3,714 3,088 
P2 6,157 69 3,500 2,588 
P3 6,371 77 3,626 2,668 
*Homozygous for reference allele; †Heterozygous; ‡Homozygous for non-
reference (alternative) allele.
 
 
 
 
In each individual, between 1,036 and 1,530 variants correspond to 
putatively novel alleles not reported in the Ensembl variation database 
(release #67). A frequency filter was used to exclude “variants” that are 
either the most frequent allele in populations close to the population of our 
three subjects (southern Italian), or present with a frequency too high to be 
consistent with pathogenicity within these or other populations. For each 
subject, the number of variants with a non-reference allele frequency greater 
than a given threshold value (0.5, 0.1, 0.05 and 0.01) is reported in Table 9.  
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Table 9. Evaluation of common allele frequency. High Confidence 
reference/alternative (r/a), alternative/alternative (a/a) is the set of HC 
variants refined by removing variants which did not pass the binomial exact 
test. EUR indicates the number of variants which could be discarded 
because the supposed alternative allele has frequency greater than the 
indicated threshold in the 1000 Genomes phase 1 EUR (Europeans) super 
population; similarly ASN !EUR, AFR !EUR, AMR !EUR and ALL !EUR 
are variants, where the supposed alternative allele frequency is greater than 
the indicated threshold, for ASN (East Asian), AFR (African), AMR (Ad 
Mixed American) and ALL (all together) super populations respectively. 
For the non-European populations only variants not already above threshold 
in the EUR super population have been counted. 
Subject HC r/a, 
a/a 
Allele 
frequency 
EUR ASN 
!EUR  
AFR 
!EUR 
AMR 
!EUR 
All 
!EUR 
P1 6,802 >0.50 1,854 276 356 139 517 
>0.10 3,312 80 119 35 170 
>0.05 3,452 66 55 42 91 
>0.01 3,589 15 12 22 30 
P2 6,088 >0.50 1,767 254 336 128 496 
>0.10 3,166 107 160 95 200 
>0.05 3,367 38 83 25 99 
>0.01 3,515 7 36 18 44 
P3 6,294 >0.50 1,790 361 354 163 547 
>0.10 3,238 65 121 57 160 
>0.05 3,392 34 73 37 88 
>0.01 3,540 4 18 14 26 
P, patient; HC, high confidence; r/a, reference/alternative; a/a, 
alternative/alternative. 
 
 
Variants in which the alternative allele frequency is greater than 0.05 
in the EUR super-population were filtered out to produce the “Final” set 
(3,350, 2,721 and 2,902 variants for patient 1, 2 and 3 respectively). This 
multistep selection/annotation procedure is reported in Figure 10. 
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Figure 10. Variants prioritization pipeline. 
 
 
 
The above mentioned pipeline produces a prioritized short-list of 
well-annotated variants that may be used to search for pathogenetic changes 
related to HCM onset and/or clinical features (Table 10).  
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Table 10. Number of variants in the final set annotated according to 
their predicted features.  
  Patients P1 P2 P3 
Number of variants in the final set 3,350 2,721 2,902 
Protein 
coding 
Synonymous 123 128 131 
Non-synonymous (possibly 
deleterious)* 
60 (11) 61 (8) 73 (7) 
Frameshift, Loss/Gain of stop codon 6 3 6 
Transcript Intron/UTR 1,638 1,518 1,550 
Splice site 15 15 18 
Complex In/del 0 1 0 
Genome Intergenic 1,560 1,014 1,140 
Upstream/Downstream 479 422 429 
Regulatory region
† 
516 313 386 
Within nc-transcript
± 
674 633 668 
*Non-synonymous is referred to a variant resulting in an amino acid change 
in the encoded peptide sequence; it is classified as being possibly 
deleterious when SIFT (http://sift.jcvi.org/) and Polyphen 
(http://genetics.bwh.harvard.edu/pph2/) predictions on the protein function 
are concordant. 
†
Regulatory region corresponds to those annotated as such 
in ENSEMBL, being inferred from experimental data through the 
Regulatory Build process 
(http://www.ensembl.org/info/docs/funcgen/regulatory_build.html). 
±
nc-transcript is a non coding transcript annotated in ENSEMBL 
(http://www.ensembl.org) that does not contain an open reading frame. 
 
 
Reliability of the NGS-based procedure. The reliability of the NGS-
based procedure was assessed by validating the variant bases identified 
within 8 sarcomeric genes against a “best estimate” sequence obtained for 
each patient by comparative assessment of all the experimental data as 
described under Materials and Methods. The results of all parameters 
measured with both methodologies are reported in Table 11.  
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Table 11. Performance Indexes of DHPLC/Sanger and NGS methods in 
nucleotide sequence-variants detection. 
 P1  P2 
 True 
nucleotide 
change:  
n=26* 
Wild –Type 
sequence: 
n= 34,041* 
  True 
nucleotide 
change: 
n=23* 
Wild –Type 
sequence: 
n=34,044* 
 
Method        
DHPLC/Sanger        
Positive TP: 14 FP: 3 PPV: 
82.4% 
 TP: 14 FP: 2 PPV: 
87.5% 
Negative FN: 12 TN: 34,038 NPV: 
99.9% 
 FN: 9 TN: 34,042 NPV: 
99.9% 
Sensitivity % 
(95% CI) 
53.8 (33.4-73.4)   60.9 (38.5-80.3)  
Specificity % 
(95% CI) 
99.9 (99.974-99.998)   99.9 (99.979-99.999)  
NGS        
Positive TP: 25 FP: 1 PPV: 
96.2% 
 TP: 22 FP: 1 PPV: 
95.7% 
Negative FN: 1 TN: 34,040 NPV: 
99.9% 
 FN: 1 TN: 34,043 NPV: 
99.9% 
Sensitivity % 
(95% CI) 
96.2 (80.4-99.9)   95.7 (78.05-99.89)  
Specificity % 
(95% CI) 
99.9 (99.997-99.999)   99.9 (99.984-99.999)  
P1, P2, patient identification code; TP, true positive; FN, false negative; FP, 
false positive; TN, true negative; CI, confidence interval; PPV, positive 
predictive value; NPV, negative predictive value. 
*Numbers refer to bp evaluate with best estimate method, as described 
under Materials and Methods. 
 
 
The sensitivity of the NGS-based procedure was 96.2% in patient 1 
and 95.7% in patient 2; specificity was very close to 100% in both patients 
(Table 11). Also predictive values are very satisfactory, being PPV (positive 
predictive value) 96.2% and 95.7% in the two patients, and NPV (negative 
predictive value) 99.9% in both patients. The single false negative result 
obtained in both patients corresponds to an undetected deletion of one G in a 
four-G strand. Similarly, the single false positive result obtained in the two 
patients is the same and is localized within a 20-fold CA repeat. No 
mistakes occurred in single-base variants. The two mistakes reflect well 
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known shortcomings of the NGS sequencing technique [140]. The 
previously used combined DHPLC/Sanger method showed a very high 
specificity (practically 100%) comparable to that of the NGS method, but its 
sensitivity was significantly lower (53.8 and 60.9%); in fact, 12 and 9 
variants were not indentified in patient 1 and 2 respectively (Table 11). 
Further analysis of the DHPLC/Sanger false negatives revealed that 8 and 6 
of them respectively are located in a small subset of non coding genomic 
segments (half of them in a single very long 3‘UTR of the ACTC1 gene) 
that, although included in the initial target list, were outside the amplicons 
obtained for the DHPLC/Sanger analysis, although they were immediately 
upstream of their 5' UTR or downstream of their 3' UTR. Therefore, these 
nucleotide position failed to produce an unequivocal positive or negative 
result but they were not retested due to their non-coding nature. Two 
additional false negatives per patient are homozygous variations, not 
detectable by the DHPLC procedure used, which was originally designed to 
identify rare heterozygous changes. If these variants are not taken into 
account, the sensitivity of the DHPLC/Sanger method increases to 87.5 and 
93% in patient 1 and 2 respectively; these revised values are close to those 
obtained by others using the same technique [145], but are still lower than 
those obtained with the NGS-based procedure described herein (Table 11). 
Mutation identification and genotype/phenotype correlations. The 
downstream analysis of the final set of variants revealed a small number of 
variants that produced potentially “deleterious” effects on protein function 
(number of variants equal to 11, 8 and 7 in patient 1, 2 and 3, respectively). 
In patient 1 we detected a variant in the MYH7 gene (c.976G>C; p.A326P) 
that produces an alanine-proline change. Interestingly, we failed to identify 
this mutation in our previous DHPLC analysis of this region [115].
 
This 
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mutation, inherited from the patient’s healthy father, has been previously 
described in HCM patients [146]. Consequently, we suggest p.A326P is the 
disease-causing mutation in patient 1. This patient also carried a rare variant 
very close to the 3’ end of the coding region, at the 20th nucleotide in the 3’ 
UTR (c.5808+20G>A) of the MYH7 gene. This variant is reported in the 
1000-Genome Phase 1 data set with a frequency of 0.8% in the EUR super-
population. We found c.5808+20G>A in only two alleles from among 520 
chromosomes of healthy individuals (a frequency of only 0.38%), and hence 
it does not fall within the definition of a single nucleotide polymorphism. 
This variant was absent in the proband’s father, the only parent available for 
genetic testing. Patient 1 carried a third variant, a heterozygous nonsense 
mutation, in the conjoined INS-IGF2 gene (namely c.575C>T; p.Q172X) 
that occurs 28 amino acids before the 3’ end of the coding region. Also this 
variation was not found in the patient’s father. The functions of INS-IGF2 
are not completely known, although it seems to be involved in the regulation 
of insulin expression [147,148], and thus in diabetes [148,149]. Glucose 
homeostasis is not altered in patient 1, but periodic screening of blood 
glucose level would seem warranted in this case.  
In patient 2, the expected MYBPC3 c.3627+2 T>A variant 
previously identified with the DHPLC/Sanger approach [115] was readily 
identified as a splicing-related variant. As we previously reported [115], this 
mutation causes exon 32 skipping and produces a shorter mRNA than the 
wild-type mRNA. We identified and confirmed a second mutation in patient 
2, namely an indel/frameshift, in the KCNQ1 gene (g. 
2548481_2548491dup, Figure 11).  
 
56 
 
 
Figure 11. Detection pattern of the KCNQ1 sequence duplication. 
KCNQ1 c. 524_534dup was identified in patient 2. A) Sequence alignment 
of the reads in the allele carrying the variant against the reference sequence 
(first line). The duplicated nucleotides are marked in yellow. B) List of all 
variant features, including genomic coordinates and the number of total and 
variant reads (coverage). C) Duplication was confirmed by Sanger 
sequencing. Arrow indicates the duplication start points. HC, high 
confidence; nt, nucleotide. 
 
 
This mutation consists of a duplication of nucleotides 
GTGGTCCGCCT at position c.524-534, previously reported in a patient 
with long-QT syndrome [150], which results in a premature stop codon 
(p.W176Lfs*65). The retrospective examination of the patient’s ECGs 
showed a long QT trait that was interpreted simply as a secondary effect of 
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hypertrophy. Examination of patient 2’s family revealed the independent 
inheritance of these two variants (Figure 12).  
 
 
Figure 12. Pedigree of patient 2’s family. Familial segregation shows the 
MYBPC3 and KCNQ1 genotypes. The two variants were independently 
inherited by the patient and his HCM-affected brother. The arrow indicates 
the proband. 
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The patient’s mother carries the KCNQ1 variant. Her ECG showed 
no sign of LVH or of a long QT trait, but a marked sinus bradycardia (50 
bpm) without a history of athleticism. Holter ECG showed marked sinusal 
bradycardia (medium 53 bpm) without signs of a long QT syndrome, 
conduction disorders and/or arrhythmias; therefore she was enrolled in a 
cardiomyopathy monitoring program.  
We did not find variations in the conventional sarcomeric genes in 
patient 3, but we did find and confirm by Sanger sequencing a mutation 
previously associated with the short QT and Brugada syndromes [151], and 
identified in 2 of 6,752 Caucasians (rs121912775) in the ESP exome 
sequencing project (http://evs.gs.washington.edu/EVS/), the CACNA1C 
p.G490R, g.2529447G>A (Figure 13).  
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Figure 13. Detection of a missense mutation in the CACNA1C gene. The 
CACNA1C p.G490R variant was identified in patient 3. A) Alignments of 
all the reads in the allele carrying the variant against the CACNA1C 
reference sequence (first line). The yellow lettering indicates the variant 
nucleotide. B) List of all variant features, including genomic coordinates 
and the number of total and variant reads (coverage). C) Sanger 
electropherogram from the same patient confirming the variant. Arrow 
indicates the variant nucleotide. HC, high confidence; nt, nucleotide. 
 
 
Patient 3 carried a second missense variant in the CACNA1C gene: 
the novel p.E771G variant, located in the second membrane-spanning 
domain that contributes to pore formation, which is essential for the 
channelling function of the protein. CACNA1C variants have been linked to 
a number of cardiac phenotypes, including the Brugada and Timothy 
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syndromes [151-154]. Patient 3 showed a complex systemic phenotype with 
features that resembled both syndromes. Several CACNA1C polymorphisms 
are significant risk factors for bipolar disorders, schizophrenia and major 
depressive disorders [155]. With the caveat that the role of these two 
CACNA1C should be verified in functional assays, it is conceivable that, by 
modifying intracellular calcium concentration [151], the variant protein 
could impair myocyte contractility, which in turn could lead to ventricular 
hypertrophy. We were able to extend variant analysis to the patient’s two 
daughters, who were tested by Sanger sequencing; the younger one (24 
years old) was identified as a carrier of the two variations. 
Electrocardiographic and echocardiographic evaluation showed no signs of 
cardiac disease; however, like her father, she has a mild depressive disorder. 
Therefore, this daughter has been enrolled in a clinical follow-up program 
that includes identification of early signs of HCM.  
Table 12 summaryze the most interesting variants identified in the 
three analyzed subjects.  
 
Table 12. Mutations most likely to exert a pathogenic role in the 
patients analyzed. 
Pts Chr Gene Mutation 
type 
Variation
*
 
(inheritance) 
Amino acid 
change 
P 1
 † 14 MYH7 Missense c.976G>C p.A326P 
   (paternal)  
11 INS-IGF2
± 
Nonsense c.573C>T p.Q172X 
P 2 11 MYBPC3 Splicing site c.3627+2T>A / 
 (paternal) 
11 KCNQ1 Indel- 
Frameshift 
c.524-534dup 
(maternal) 
p.W176Lfs
*65 
P 3
 † 12 CACNA1C Missense c.1781G>A p.G490R 
12 CACNA1C Missense c.2625A>G p.E771G 
Pts, patient; Chr, chromosome.
*
All mutations were at heterozygous state. 
†
Patient 1’s biological mother and patient’s 3 parents were not available for 
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molecular testing. 
±
Mutation included because it produces a truncated 
protein. 
 
 
Analysis of the pooled DNA sample. The same individually 
sequenced DNAs from the three patients were also sequenced as a pooled 
DNA sample, which also contained a fourth control sample DNA. In this 
experiment, the set up produced an expected depth about double that of each 
single patient. As shown in Table 7, the fraction of covered targets is similar 
to that observed for each separate subject. The number of variants identified 
for each subject is shown in Table 13.  
 
Table 13. ‘HC’ and ‘Final’ variants identified for each subject in the 
pool. The obtained values are compared to those expected on the basis of 
the results of the single subject sequencing experiment. 
Dataset Expected Found Found (%) 
P1 HC 6,894 5,194 75.3 
P1 Final 3,350 2,113 63.1 
P2 HC 6,157 4,899 79.6 
P2 Final 2,721 1,930 70.1 
P3 HC 6,371 4,974 78.1 
P3 Final 2,902 1,941 66.9 
 
 
Comparative analysis of the identified variants (Table 14) shows that 
most allelic variants common to more than one patient were also identified 
in the pool. However, more variants were missed as their presence in the 8 
analyzed alleles decreased. 
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Table 14. Analysis of non-reference (variant) alleles found in single 
subject sequencing experiments and also identified in the pool. Variants 
missed in the pool (last column) are increasing when they are read on a rarer 
number of alleles. 
 
 Pool Variants 
Alleles Expected* Found Missed 
8/8 683 677 6 
7/8 353 353 0 
6/8 669 659 10 
5/8 717 695 22 
4/8 1,182 1,077 105 
3/8 1,090 966 124 
2/8 2,976 1,756 1,220 
1/8 4,414 1,705 2,709 
*Expected in the pool from the analysis performed in the individual patient 
samples 
 
 
4.2 Metagenomics 
 
4.2.1 Crohn disease 
A 16S rRNA NGS-based strategy was used to investigate the gut 
microbiome composition of the three collected ileum samples. High-quality 
filtered sequences were used to identify the OTUs: 705, 1,328 and 2,171 
different OTUs were obtained in the patient before (BT) and after therapy 
(AT), and in the control subject, respectively. Based on the taxonomic 
assignment of the OTUs, we characterized the ileum microbiome of our 
samples at five phylogenetic levels (from phylum to genus). As shown in 
Figure 14, Proteobacteria were more abundant, and Bacteroidetes less 
abundant, in our CD patient BT than in the control. Interestingly, the 
composition of the ileum microbiome in the patient AT was virtually the 
same as in the control (Figure 14).  
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Figure 14. Composition of the ileum microbiome characterized in the 
control subject and in the Crohn patient BT and AT by NGS. (a) 
Phylum-level classification shows the reduction of Bacteroidetes and the 
significant prevalence of Proteobacteria in the patient-BT vs the control and 
the patient-AT. (b) The Heatmap table highlights in brownish red the most 
significant alterations in the bacterial composition of gut microbiome 
detected in the CD patient BT; the numerical figures indicate the number of 
bacterial families sequenced in each patient.  
 
 
Moreover, our data support the reduced bacterial diversity of the CD 
microbiome. In fact, the Shannon Diversity Index Score was significantly 
lower (p <0.05) in our CD patient before therapy than after therapy and also 
when compared with the control (Figure 15).  
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Figure 15. The mean Shannon Diversity Index Score. Values were 
significantly lower in the patient before therapy (patient-BT) than in the 
control subject and in the patient after therapy (patient-AT) (* p < 0.05).  
 
 
4.2.2 Celiac disease 
By 16S bacterial rRNA sequencing we preliminarily obtained 
214,999 post quality filtered sequences. After the OTUs picking procedure, 
we identified a total of 155,281 sequences corresponding to 6,624 OTUs, of 
which 1% resulted unclassified and 99% were assigned to known bacteria 
after the taxonomic classification. Globally, including singleton and 
doubleton sequences, the non-filtered per frequency taxonomic assignment 
reported a total of 19 Phyla, 40 Classes, 81 Orders, 159 Families and 328 
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Genera of which only 22 species were identified. After filtering per 
frequency higher than 1% a total of 5 Phyla, 6 Classes, 7 Orders, 10 
Families, and 10 different genera resulted (Table 15). 
 
 
Table 15. 16S bacterial RNA samples metadata, globally considered in 
the study population. 
 NGS-based duodenal microbiome profiles 
N QF reads 214,999 
N post OTU picking reads 155,281 
N OTUs 6,624 (1% unclassified; 99% assigned) 
Non-filtered-per- 
frequency taxonomic 
assignment 
 19 phyla 
 40 classes 
 81 orders 
 159 families 
 328 genera 
Filtered-per-frequency 
>1% taxonomic 
assignment 
 5 phyla 
 6 classes 
 7 orders 
 10 families 
 10 genera 
NGS: next generation sequencing; N: number; QF: quality filtered; OTU: 
operational taxonomic units. 
 
 
 
The 5 identified phyla, globally considered, were: Proteobacteria 
(44.2%), Actinobacteria (15.8%), Bacteroidetes (15.8%), Firmicutes 
(14.9%), and Fusobacteria (9.3%) (Figure 16A). In particular, the majority 
of known bacteria sequences (>10% of mean frequency among the three 
groups) were classified within six genera: Acinetobacter (16.5%), Neisseria 
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(15.5%), Streptococcus (14.9%), Propionibacterium (13.6%) Haemophilus 
(12.3%), and Prevotella (Prevotellaceae family, 10.2%). The less abundant 
genera (2-10% of frequency) identified were: Fusobacterium (9.3%), 
Prevotella (Paraprevotellaceae family, 2.9%), Porphyromonas (2.6%), 
Rothia (2.2%) (Figure 16E). 
The microbiome profiles, as analyzed in the 3 study groups, at the 
phylum level show to be quiet similar for Actinobacteria and Bacteroidetes, 
while in the active CD patients a trend in the increase of Proteobacteria and 
Fusobacteria and in the decrease of Firmicutes was observed, as compared 
with the other 2 groups (Figure 16A). Among the Proteobacteria phylum , 
bacteria of the Betaproteobacteria class (p= 0.01), the Neisseriales order 
(p= 0.02), the Neisseriaceae family (p= 0.03) and the Neisseria genus (p= 
0.03) were significantly more abundant in the active CD patients (Figure 
16B−E). In particular, the latter genus was more abundant in the active CD 
patients (32%) than in the GFD patients (4%) and controls (10%) (Figure 
16E). The Neisseria genus was the most represented genus (99.8%) 
associated to the Neisseriaceae family. Within the Proteobacteria phylum, 
species of the Gammaproteobacteria class were significantly (p=0.03) less 
abundant in active-CD patients than in the other groups (Figure 16C).  
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Figure 16. Duodenal microbiome taxonomic composition (from phylum 
to genus level) in controls, active and GFD CD patients. (A) Phylum 
level classification among the tested groups (controls, CD patients, GFD 
patients) reporting the relative abundance. Proteobacteria was the most 
represented phylum in all the groups with an average of 44.2%. No 
significant differences were found in each of the identified phyla among 
groups. (B) Class level classification among the three groups showed a trend 
in reduction in the Betaproteobacteria (p= 0.01) class in GFD patients (4%) 
and controls (10%) compared to CD patients (32%). The 
Gammaproteobacteria class was observed to be decreased (p= 0.03) in CD 
patients (18%), compared with controls (32%) and GFD patients (35%). (C) 
Order level classification reported a significant difference (p= 0.02) in the 
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Neisseriales order in the three groups, controls (~10%), GFD patients 
(~4%), CD patients (~32%). (D) Family level classification also showed a 
significant difference (p= 0.03) in the Neisseriace family, observed to be 
decreased in controls (~10%) and GFD patients (4%) groups, compared to 
CD patients (~32%). (E) The genus level comparison among groups 
highlighted a statistical significance difference (p= 0.03) in the genus 
Neisseria which abounded in the active CD patients (32%) respect to 
controls (10%) and GFD patients (4%). Taxa, in parenthesis, refer to 
phylum which genus belongs to. Error bars indicate standard error. 
Asterisks refer to taxa that reported a statistical significance difference 
among the three groups (p≤ 0.05, ANOVA). 
 
 
Alpha diversity, or the within sample diversity, was computed using 
two different metrics: the Faith's Phylogenetic Diversity (PD) richness 
estimator [156], and the observed species metric, which reports the number 
of different bacterial OTUs at a rarefaction depth of 854 sequences/sample. 
The obtained alpha rarefaction curves showed that bacterial community 
richness did not differ between CD-patients and controls (Figures 17A and 
B). Beta diversity of bacterial communities is presented in the unweighted 
and weighted UniFrac PCoA plots (Figures 17C and D). The beta diversity 
computed with unweighted Unifrac method, was statistically significant 
within the three groups (p= 0.015, R
2
= 0.08; ADONIS). Also, the beta 
diversity computed with weighted Unifrac method presented a significant 
difference among the three groups of study (p= 0.029, R= 0.14; ANOSIM). 
Interestingly, this analysis suggests that active and GFD CD gut 
communities are more similar to each other than control communities are to 
each other, indicated by the tighter clustering of active and GFD CD points 
than control points in Figure 17, with the only exception of a 14 years old 
active-CD patient (indicated by a black arrow). The significant differences 
found suggest that there are distinct community types associated with active 
CD and controls. This may mean that active CD is associated with a 
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particular overall gut microbial community signature. This signature varies 
across individuals, but degree of variability is less than that across healthy 
individuals. 
 
Figure 17. Bacterial diversity analysis. Alpha diversity, measured using 
Faith’s Phylogenetic Diversity estimator (A) or the “observed species” 
method (B), shows no difference between the 3 groups. Error bars represent 
standard error of the mean. (C)-(D) Beta diversity computed with the 
unweighted (C) and weighted (D) UniFrac distances shows a phylogenetic 
relationship between active and GFD patients, both of which are distinct 
from the controls which reported a random distribution [(p= 0.015, R2= 
0.08) ADONIS)] (C), [(p= 0.029, R= 0.14) ANOSIM] (D). Black arrows 
indicate the only 14 years old female in the active CD patients.  
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V. DISCUSSION 
 
5.1 Targeted DNA Sequence Capture 
A DNA sequence capture approach followed by NGS was 
successfully applied to the simultaneous analysis of a large panel of genes 
possibly related to cardiomyopathies. In particular, a panel of 202 candidate 
genes, encoding proteins involved in heart functions or that might be related 
to the development of cardiomyopathies, was used to design a custom array 
for targeted enrichment before NGS analysis, thus increasing the 
effectiveness of HCM molecular diagnosis over currently available 
procedures.  
Limiting the analysis to the 8 sarcomeric genes previously analyzed 
by a combined DHPLC/Sanger approach [115], all the Sanger-confirmed 
variants previously identified in patients 1 and 2 were confirmed by the 
NGS procedure described herein except one. With the described procedure, 
we also detected 21 variants that were missed by the previous DHPLC 
screening. To evaluate the reliability of the new NGS-based method in 
detecting variants, we compared its sensitivity and specificity to those of the 
previously used DHPLC/Sanger method. As shown in Table 11, NGS was 
very sensitive and specific in detecting mutations, while the sensitivity of 
the DHPLC/Sanger procedure was much lower (about 50-60%). These low 
sensitivity values depend on the experimental design used for the 
DHPLC/Sanger approach, which was designed to detect variants within the 
exon sequences, and is expected to be less sensitive, for example, in 
highlighting changes in the untranslated regions or close to the ends of the 
analyzed segments – a limitation that does not apply to the NGS approach. 
In fact, when variants expected to be undetectable by DHPLC/Sanger 
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sequencing, i.e. variants outside amplicons and homozygous variants, are 
not taken into account in calculating sensitivity, the results become 
comparable to those of other reports [145], although still remaining worse 
than the new NGS-based procedure.  
The above considerations only refer to a small proportion (1%) of 
the entire target region analyzed by the NGS-based method. Unlike the 
DHPLC method, the NGS procedure produces results on a set of 202 genes, 
corresponding to about 4M bases of the coding genomic sequence. It is 
noteworthy that even on the limited 8-gene set the performance of the NGS-
based method is better. As stated elsewhere [157], it remains in fact to be 
established whether the diagnostic output of a test that detects a large 
number of variants in a relatively large number of genes might be compared 
with a test that detects almost all variants, but in a low number of genes. 
In diagnostic terms, the high throughput sequencing procedure 
enabled us: (i) to identify a known HCM-causative mutation in patient 1, 
who went previously undiagnosed; (ii) to better delineate the molecular 
alteration underlying the phenotype of patient 2 by detecting the presence in 
this HCM subject of a mutation causative of long QT syndrome [150,158]; 
and (iii) to postulate that the HCM observed in patient 3 was due to 
CACNA1C-related mutations (Timothy syndrome) [152-154].  
Although the bioinformatic tools we used eliminate variants that are 
most likely bereft of clinical significance, the real pathogenic role of a given 
variant can only be determined with functional studies and/or family 
segregation analysis to evaluate genotype-phenotype correlations within 
each family. The variants we identified in the present work (see Table 12) 
should be classified as “possibly pathogenic” because they fulfil at least one 
of the following conditions: (i) previous findings showing that they are 
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disease-causing (4 of them); (ii) their presence on genes known to cause 
HCM (2); and (iii) the presence of stop codons indicating a truncated 
protein (1) (Table 12). Further procedures are of course necessary to 
confirm the causative origin of mutations in order to better rationalize the 
genotype-phenotype relationship within each family and to better 
understand the molecular basis of the alteration induced by each mutational 
event. The annotations and the prioritization strategy described herein could 
help to simplify these steps.  
Sequencing of several patients in a single run is an additional 
improvement over the conventional Sanger procedure in terms of time and 
sequencing throughput. We applied our procedure to a pool containing DNA 
from the three patients to evaluate the feasibility of sequencing several 
patients simultaneously. Target enrichment and sequencing coverage were 
highly consistent with the values found in the three separate samples. 
However, not all variants detected in the individual DNA samples were 
identified in the pool (Tables 13 and 14), as expected considering the 
reduced overall sequence depth. The sensitivity of the pool-based approach 
may easily be enhanced, by increasing the sequencing depth while still 
saving on the costs and workload associated with library preparation and 
titration. The use of tags to selectively label the DNA of single patients in 
multiplexing experiments would have the advantage of univocally assigning 
the sequencing reads to each patient at the cost of a slightly more complex 
experiment. 
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5.2 Metagenomics 
 
5.2.1 Crohn disease 
Inflammatory bowel diseases are chronic recurrent diseases of the 
gastrointestinal tract, and are caused by a combination of genetic and 
environmental factors, including the gut microbiota. A number of studies 
have reported significant alterations of gut microbial composition in IBD 
patients compared with not affected individuals [104,159-161]. Not only  
IBD patients have an altered rate of Bacteroidetes, Proteobacteria and 
Firmicutes colonization, but the bacterial diversity of their microbiome is 
generally lower than that of controls. In this context, we characterized the 
16S rRNA ileum-associated microbiome of a Crohn-affected patient at 
diagnosis and after nutritional therapy. This therapy is known to be effective 
in the reduction of gut inflammation; we found that it was effective also in 
the restoring of the gut microbial balance. In fact, at follow-up, the 
microbial composition did not differ between the patient and control.  
Although our findings were obtained in one case-control study, and 
therefore may be considered preliminary, they strongly suggest that 
nutritional therapy can improve the inflammatory status of Crohn disease by 
restoring the composition of the mucosal microbiome. This case of Crohn 
disease gut microbiome dysbiosis restored by nutritional therapy can be 
considered proof-of-concept to test a similar approach in several 
laboratories and also as clinical preliminary assessment for future research 
and possibly clinical trials. 
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5.2.2 Celiac disease 
Alterations in the gut microbiota and such other factors as haplotypes, 
breastfeeding, type of delivery, clinical manifestations, time of gluten 
exposure, and age of onset, have been implicated in CD, but the results 
reported so far are inconclusive particularly due to differences in the 
populations studied, and in the samples and techniques used [87,162-165]. 
In the attempt to shed light on the link between the gut mucosal microbial 
community and CD onset, we exploited the NGS technique to examine the 
gut microbiome composition in an Italian adult cohort of CD patients, either 
active or on a GFD, and in control subjects. We found significant 
differences between the three groups studied, which indicates that the 
microbiota distinguishes these groups. Notably, diversity analysis revealed a 
tighter clustering of active and GFD CD, suggesting that active and GFD 
CD microbiomes are more similar to each other than the control microbiome 
is to each of them. Interestinly, the Neisseria genus, which belongs to the 
Proteobacteria phylum, was more abundant in active CD patients than in 
the other two groups. This confirm the previous finding that species of the 
Neisseria genus were more abundant in the duodenum of adult active CD 
patients than in controls [164,166]. 
Even if the significance of the observed differences has to be 
assessed by further evaluations to define their potential pathogenetic role in 
celiac disease development, we were able to define, using a NGS-based 
method, the whole duodenal microbiome signature of adult patients affected 
by active and GFD CD. 
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V. CONCLUSIONS 
 
The main aim of this PhD project was to use NGS-based strategies to 
study the molecular basis of human diseases. Two different approaches, 
target DNA sequence capture and metagenomics, were used to assess the 
above mentioned issue and were successfully applied to the study of 
inherited cardiomyopathies and Crohn and celiac diseases, respectively. The 
data shown here strongly reinforce the concept that NGS techniques open a 
new era in the search for new disease-causing genes and/or novel modifier 
genes and in the study of disease pathogenesis.  
Taken together, all the above results indicate that the NGS-based 
procedures described here can be easily applied to increase our 
understanding of the molecular basis of human diseases and that they can be 
useful also for routine diagnostic purposes.  
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APPENDIX 1 
 
List of the genes selected to perform the custom array. 
Gene Description 
(Functional 
classes) 
Gene trIDs
* 
Chr† 
Segs 
(n)‡ 
Segs 
(bp)§ 
Transc 
(n)|| 
CARDIOMYOPATHY
-ASSOCIATED 
      
actin, alpha 1, skeletal 
muscle 
ACTA1 NM_001100 1 1 3852 1 
cardiac muscle alpha 
actin 1 proprotein 
ACTC1 NM_005159 15 2 8523 1 
calreticulins Ca-binding 
chaperons 
CALR3 NM_145046 19 7 8574 1 
calsequestrin 2 (cardiac 
muscle) 
CASQ2 NM_001232 1 11 13711 1 
caveolin 3≠ CAV3 
NM_001234,NM_03
3337 
3 2 3423 2 
cytochrome c oxidase 
assembly protein≠ 
COX15 
NM_078470,NM_00
4376 
10 8 15983 2 
cysteine and glycine-rich 
protein 3≠ 
CSRP3 
NM_003476,NM_00
1127656 
11 6 7347 2 
Desmin DES NM_001927 2 4 7255 1 
frataxin≠ FXN 
NM_000144,NM_18
1425 
9 5 7275 2 
junctophilin≠ JPH2 
NM_020433,NM_17
5913 
20 6 12735 2 
lysosomal-associated 
membrane protein≠ 
LAMP2 
NM_002294,NM_00
1122606,NM_01399
5 
X 8 19044 3 
LIM domain binding 3 LDB3 
NM_001080115,NM
_001080114,NM_00
1080116,NM_00707
8 
10 13 21033 4 
myosin binding protein 
C, cardiac 
MYBPC
3 
NM_000256 11 7 19751 1 
myosin, heavy chain 6, 
cardiac muscle, alpha 
MYH6 NM_002471 14 8 24026 1 
myosin, heavy chain 7, 
cardiac muscle, beta 
MYH7 NM_000257 14 4 23206 1 
slow cardiac myosin 
regulatory light chain 2 
MYL2 NM_000432 12 5 6796 1 
myosin, light chain 3, 
alkali; ventricular, 
skeletal, slow 
MYL3 NM_000258 3 4 5307 1 
myosin light chain kinase 
2 
MYLK2 NM_033118 20 5 10877 1 
myosin VI MYO6 NM_004999 6 28 40652 1 
myozenin 2 MYOZ2 NM_016599 4 5 8124 1 
NADH dehydrogenase 
(ubiquinone) 
flavoprotein 2 
NDUFV
2 
NM_021074 18 7 7918 1 
obscurin, cytoskeletal 
calmodulin≠ 
OBSCN 
NM_052843,NM_00
1098623 
1 23 82957 2 
phospholamban PLN NM_002667 6 2 3716 1 
AMP-activated protein 
kinase gamma2 subunit≠ 
PRKAG
2 
NM_024429,NM_00
1040633,NM_01620
7 16 20335 3 
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3 
solute carrier family 25 
SLC25A
4 
NM_001151 4 2 4750 1 
sorcin≠ SRI 
NM_198901,NM_00
3130 
7 6 10155 2 
titin-cap (telethonin) TCAP NM_003673 17 1 2210 1 
troponin C type 1 TNNC1 NM_003280 3 2 3474 1 
troponin I, cardiac TNNI3 NM_000363 19 3 5486 1 
troponin T type 2, 
cardiac≠ 
TNNT2 
NM_001001430,NM
_000364,NM_00100
1431,NM_00100143
2 
1 8 14014 4 
tropomyosin 1 alpha 
chain≠ 
TPM1 
NM_001018005,NM
_001018004,NM_00
1018008,NM_00036
6,NM_001018020,N
M_001018007,NM_0
01018006 
15 8 14192 7 
titina≠ TTN 
NM_003319,NM_13
3378,NM_133432,N
M_133437,NM_1333
79 
2 44 
22958
4 
5 
vinculin isoform meta-
VCL≠ 
VCL 
NM_014000,NM_00
3373 
10 18 25559 2 
integrin, alpha 8 ITGA8 NM_003638 10 26 31822 1 
cardiac ankyrin repeat 
protein 
CARP NM_014391 10 4 8118 1 
v-raf-1 murine leukemia 
viral oncogene homolog 
1 
RAF1 NM_002880 3 10 15534 1 
METABOLIC HCM       
acid-alpha glucosidase GAA NM_000152 17 5 14287 1 
amilo-1-6-glucosidase AGL NM_000642 1 19 31359 1 
acid-beta glucosidase GBA NM_001005741 1 2 8923 1 
ION CHANNELS       
potassium voltage-gated 
channel, KQT-like≠ 
KCNQ1 
NM_181798,NM_00
0218 
11 12 19308 2 
potassium channel 
voltage-gated, subfamily 
H≠ 
KCNH2 
NM_172056,NM_00
0238,NM_172057 
7 7 15667 3 
potassium channel 
voltage-gated ISK-
related subfamily 
member 1≠ 
KCNE1 
NM_000219,NM_00
1127670,NM_00112
7669,NM_00112766
8 
21 4 8545 4 
potassium channel 
voltage-gated ISK-
related subfamily 
member 2 
KCNE2 NM_172201 21 2 2805 1 
sodium channel, voltage-
gated, type V, alpha 
subunit≠ 
SCN5A 
NM_198056,NM_00
1099405,NM_00109
9404,NM_000335 
3 23 35206 4 
calcium channel, 
voltage-dependent, L-
type, alpha-1C subunit ≠ 
CACNA
1C 
NM_001129830,NM
_001129827,NM_00
1129829,NM_00071
9,NM_001129831,N
M_001129839,NM_0
01129836,NM_0011
29833,NM_0011298
32,NM_001129834,N
M_001129835,NM_0
01129837,NM_0011
12 37 58658 20 
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29838,NM_0011298
40,NM_001129841,N
M_001129842,NM_0
01129843,NM_0011
29844,NM_0011298
46,NM_199460 
sodium channel, voltage-
gated, type IV, beta 
subunit 
SCN4B NM_174934 11 4 9483 1 
potassium channel, 
inwardly rectifying, 
subfamily J, member2 
KCNJ2 NM_000891 17 2 7388 1 
MEMBRANE 
CHANNELS 
      
solute carrier family 9, 
isoform A3 
SLC9A3 NM_004174 5 8 14281 1 
solute carrier family 9, 
isoform A2 
SLC9A2 NM_003048 2 10 16646 1 
solute carrier family 9, 
isoform A4 
SLC9A4 NM_001011552 2 11 15714 1 
ATPase Ca(2+)-
transporting, slow-
twitch≠ 
ATP2A2 
NM_001681,NM_17
0665 
12 10 23130 2 
solute carrier family 6, 
member 4 
SLC64A  
(SLC6A
4) 
NM_001045 17 9 15765 1 
GROWTH FACTORS       
transforming growth 
factor, beta 1 
TGF-b 
(TGFB1) 
NM_000660 19 5 8407 1 
fibroblast growth factor 1 
(acidic) ≠ 
FGFa 
(FGF1) 
NM_000800,NM_03
3137,NM_033136 
5 4 6346 3 
insulin-like growth factor 
1≠ 
IGF1 
NM_001111285,NM
_001111284,NM_00
1111283,NM_00061
8 
12 6 13820 4 
early growth response 1 EGR1 NM_001964 5 1 4825 1 
insulin like growth factor 
2≠ 
IGF2 
NM_001127598,NM
_000612,NM_00100
7139 
11 6 13161 3 
FACTORS 
INVOLVED IN 
CARDIOMYOCYTE 
GROWTH AND 
CONTRACTILITY 
      
beta1 adrenergic receptor 
1 
ADRB1 NM_000684 10 1 3863 1 
angiotensin receptor 1≠ AGTR1 
NM_004835,NM_00
0685,NM_032049,N
M_009585,NM_0318
50 
3 5 7576 5 
endothelin 1 EDN1 NM_001955 6 4 6268 1 
endothelin receptor, type 
A 
EDNRA NM_001957 4 7 11745 1 
angiotensinogen AGT NM_000029 1 4 7451 1 
endothelin receptor. 
Type B≠ 
EDNRB 
NM_000115,NM_00
3991,NM_00112265
9 
13 5 10584 3 
Protein kinase C, alpha PRKCA NM_002737 17 15 25199 1 
INFLAMMATION       
interleukin 6 IL6 NM_000600 7 3 5003 1 
interleukin 6 receptor≠ IL6R 
NM_000565,NM_18
1359 
1 8 13285 2 
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phospholipasi A2 
PLA2G1
B 
NM_000928 12 3 4367 1 
phospholipase D1, 
phosphatidylcholine-
specific≠ 
PLD1 
NM_002662,NM_00
1130081 
3 22 30391 2 
phospholipase D1, 
glycosylphosphatidylinos
itol-specific≠ 
GPLD1 
NM_177483,NM_00
1503 
6 16 23339 2 
nuclear factor kappa-B, 
subunit 1 
NFKB1 NM_003998 4 20 26029 1 
interleukin 13 IL13 NM_002188 5 2 3882 1 
toll-like receptor 4 
precursor 
TLR4 NM_138554 9 3 8504 1 
inhibitor of kappa light 
polypeptide 
IKBKB NM_001556 8 14 21503 1 
interleukin 23, alpha 
subunit 
IL23A NM_016584 12 1 2533 1 
toll-like receptor 2 TLR2 NM_003264 4 3 6405 1 
interleukin 27 IL27 NM_145659 16 4 5132 1 
prostaglandin-
endoperoxide synthase 2 
PTGS2 NM_000963 1 1 9589 1 
macrophage migration 
inhibitory factor 
MIF NM_002415 22 1 1846 1 
interleukin 17A IL17A NM_002190 6 3 4862 1 
interleukin 12B IL12B NM_002187 5 6 9479 1 
C-reactive protein, 
pentraxin-related 
CRP NM_000567 1 1 3302 1 
arachidonate 
lipoxygenase 12 
ALOX12 NM_000697 17 5 10490 1 
arachidonate 
lipoxygenase 15 
ALOX15 NM_001140 17 4 9462 1 
arachidonate 
lipoxygenase 15, type b≠ 
ALOX15
B 
NM_001039130,NM
_001039131,NM_00
1141 
17 3 8768 3 
arachidonate 
lipoxygenase 5 activating 
protein 
ALOX5
AP 
NM_001629 13 5 5878 1 
arachidonate 5-
lipoxygenase 
ALOX5 NM_000698 10 9 13759 1 
interleukin 1, alpha 
proprotein 
IL1A NM_000575 2 4 9444 1 
interleukin 10 IL10 NM_000572 1 3 5783 1 
chemokine (C-C motif) 
receptor 2≠ 
CCR2 
NM_000647,NM_00
0648 
3 2 5769 2 
chemokine (C-X3-C 
motif) 
CX3CR1 NM_001337 3 2 5110 1 
chemokine binding 
protein 2 
CCBP 
(CCBP2) 
NM_001296 3 3 5963 1 
phospholipase A2 PLA2G7 NM_005084 6 8 12235 1 
small inducible cytokine 
A2 precursor 
CCL2 NM_002982 17 1 2926 1 
prostaglandin-
endoperoxide synthase 
1≠ 
PTGS1 
NM_080591,NM_00
0962 
9 7 12923 2 
signal transducer and 
activator of 
transcription≠ 
STAT3 
NM_213662,NM_13
9276,NM_003150 
17 11 20992 3 
selenoprotein S SEPS1 NM_000808 X 10 12795 1 
tumor necrosis factor 
(ligand) superfamily, 
member 10 
TNFSF1
0 
NM_003810 3 5 6764 1 
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chemokine (C-X-C 
motif) ligand 12≠ 
CXCL12 
NM_199168,NM_00
0609,NM_00103388
6 
10 5 10238 3 
interleukin 1, beta IL1B NM_000576 2 3 6794 1 
chemokine (C-C motif) 
receptor 6≠ 
CCR6 
NM_031409,NM_00
4367 
6 3 6786 2 
interleukin 12A IL12A NM_000882 3 3 5923 1 
interleukin 11 IL11 NM_000641 19 3 5667 1 
interleukin 8 receptor, 
beta 
IL8RB NM_001557 2 3 5862 1 
interleukin 18 IL18 NM_001562 11 6 7151 1 
interleukin 1 receptor, 
type I 
IL1R NM_000877 2 6 14049 1 
tumor necrosis factor 
alpha 
TNF NM_000594 6 1 3764 1 
TNF receptor-associated 
factor 4 
TRAF4 NM_004295 17 2 5999 1 
interferon, alpha 1 IFNA1 NM_024013 9 1 1877 1 
interferon, beta 1 IFNB1 NM_002176 9 1 1841 1 
desmoplakin≠ DSP 
NM_004415,NM_00
1008844 
6 8 28150 2 
complement component 
5 preproprotein 
C5 NM_001735 9 32 43248 1 
small inducible cytokine 
A27 precursor 
CCL27 NM_006664 9 1 1798 1 
interleukin 11 receptor, 
alpha≠ 
IL11RA 
NM_004512,NM_14
7162 
9 4 8591 2 
chemokine (C-C motif) 
ligand 7 
CCL7 NM_006273 17 1 3018 1 
chemokine (C-X-C 
motif) ligand 2 
CXCL2 NM_002089 4 1 3245 1 
interleukin 17F precursor IL17F NM_052872 6 3 3811 1 
interleukin 27 receptor, 
alpha 
IL27RA NM_004843 19 6 11056 1 
chemokine (C-X-C 
motif) ligand 13 
CXCL13 NM_006419 4 4 5502 1 
suppressor of cytokine 
signaling 3 
SOCS3 NM_003955 17 1 4298 1 
leukotriene B4 receptor LTB4R NM_181657 14 1 4637 1 
chemokine (C-C motif) 
receptor 1 
CCR1 NM_001295 3 2 4678 1 
interleukin-1 receptor-
associated kinase 3 
IRAK3 NM_007199 12 9 12273 1 
chemokine-like receptor 
1 isoform b 
CMKLR
1 
NM_004072 12 3 4889 1 
vascular cell adhesion 
molecule 1≠ 
VCAM1 
NM_001078,NM_08
0682 
1 7 11559 2 
MAP KINASES       
mitogen-activated 
protein kinase 1≠ 
MAPK1 
NM_002745,NM_13
8957 
22 8 14393 2 
mitogen-activated 
protein kinase 3≠ 
ERK1 
(MAPK3
) 
NM_001040056,NM
_001109891,NM_00
2746 
16 4 6964 3 
mitogen-activated 
protein kinase 14 ≠ 
MAPK1
4 
NM_139014,NM_13
9013,NM_139012,N
M_001315 
6 9 15910 4 
mitogen-activated 
protein kinase 8 ≠ 
MAPK8 
NM_002750,NM_13
9049,NM_139047,N
M_139046 
10 8 10827 4 
mitogen-activated 
protein kinase 
MAP3K
1 
NM_005921 5 11 22936 1 
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TRANSCRIPTIONAL 
FACTORS 
      
nuclear factor of 
activated T cells 5 ≠ 
NFAT5 
NM_173214,NM_13
8713,NM_006599,N
M_001113178,NM_1
38714 
16 11 28339 5 
peroxisome proliferator-
activated receptor-alpha 
≠ 
PPARA 
NM_001001928,NM
_005036 
22 9 19058 2 
peroxisome proliferator-
activated receptor-delta 
PPARD NM_006238 6 7 10921 1 
peroxisome proliferator-
activated receptor-
gamma≠ 
PPARG 
NM_005037,NM_13
8712,NM_138711,N
M_015869 
3 9 12188 4 
MADS box transcription 
enhancer factor 2, 
polypeptide A≠ 
MEF2A 
NM_001130927,NM
_001130928,NM_00
1130926,NM_00558
7 
15 11 17570 4 
MADS box transcription 
enhancer factor 2, 
polypeptide B≠ 
MEF2B 
NM_001134794,NM
_001134795,NM_00
5919 
19 7 11212 3 
MADS box transcription 
enhancer factor 2, 
polypeptide C≠ 
MEF2C 
NM_002397,NM_00
1131005 
5 11 19351 2 
GATA-binding protein 4 GATA4 NM_002052 8 7 10415 1 
GATA-binding protein 5 GATA5 NM_080473 20 3 7206 1 
GATA-binding protein 6 GATA6 NM_005257 18 6 9595 1 
forkhead box J1 
HFH4 
(FOXJ1) 
NM_001454 17 2 4377 1 
MADS box transcription 
enhancer factor 2, 
polypeptide D 
MEF2D NM_005920 1 7 15031 1 
V-FOS FBJ murine 
osteosarcoma viral 
oncogene homolog 
FOS NM_005252 14 1 4383 1 
heart and neural crest 
derivatives-expressed 1 
HAND1 NM_004821 5 2 3739 1 
heart and neural crest 
derivatives-expressed 2 
HAND2 NM_021973 4 2 4370 1 
MK2 homeobox 5 NKX2-5 NM_004387 5 2 3587 1 
NOTCH, Drosophila, 
homolog of, 1 
NOTCH
1 
NM_017617 9 9 28501 1 
ROS PRODUCTION       
NADPH oxidase 1≠ NOX1 
NM_007052,NM_01
3955 
X 5 10228 2 
xanthine dehydrogenase XDH NM_000379 2 23 36677 1 
nitric oxide synthase 1 NOS1 NM_000620 12 25 34743 1 
nitric oxide synthase 2A NOS2A NM_000625 17 14 26423 1 
nitric oxide synthase 3 NOS3 NM_000603 7 9 18054 1 
HISTONE 
(DE)ACETYLASES 
      
histone acetyltransferase 
1≠ 
HAT1 
NM_001033085,NM
_003642 
2 8 10753 2 
histone deacetylase 1 HDAC1 NM_004964 1 7 11303 1 
histone deacetylase 2 HDAC2 NM_001527 6 8 18079 1 
histone deacetylase 3 HDAC3 NM_003883 5 5 9428 1 
histone deacetylase 4 HDAC4 NM_006037 2 24 34315 1 
histone deacetylase 5≠ HDAC5 
NM_005474,NM_00
1015053 
17 7 18729 2 
histone deacetylase 6 HDAC6 NM_006044 X 6 15180 1 
histone deacetylase 7A≠ HDAC7 NM_001098416,NM 12 9 18377 2 
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A _015401 
histone deacetylase 8 HDAC8 NM_018486 X 9 11987 1 
histone deacetylase 9≠ HDAC9 
NM_058176,NM_17
8425,NM_178423,N
M_014707,NM_0581
77 
7 22 30572 5 
FKBP12-rapamycin 
complex-associated 
protein 1 
FRAP1 NM_004958 1 34 52998 1 
OTHERS       
RAS homolog gene 
family, member A 
RHOA NM_001664 3 5 6926 1 
RAS-related C3 
botulinum toxin substrate 
1≠ 
RAC1 
NM_006908,NM_19
8829,NM_018890 
7 7 9751 3 
sperm associated antigen 
6 
SPAG6 NM_012443 10 9 12552 1 
sperm associated antigen 
16 
SPAG16 NM_024532 2 16 18190 1 
cell division cycle 42≠ CDC42 
NM_044472,NM_00
1791,NM_00103980
2 
1 6 9905 3 
Coiled-coil domain-
containing protein 63 
FLJ3584
3 
(CCDC6
3) 
NM_152591 12 11 12214 1 
Coiled-coil domain-
containing protein 114 
FLJ3292
6 
(CCDC1
14) 
NM_144577 19 2 5262 1 
actin-binding RHO-
activating protein 
ABRA NM_139166 8 2 4756 1 
RHO-associated coiled-
coil-containing protein 
kinase1 
ROCK1 NM_005406 18 24 34738 1 
ubiquitin-specific 
protease 7 
USP7 NM_003470 16 13 26583 1 
Myocardin MYOCD NM_153604 17 13 15830 1 
serum response factor SRF NM_003131 6 4 9434 1 
homeodomain-only 
protein≠ 
HOP 
(HOPX) 
NM_139212,NM_13
9211,NM_032495 
4 4 5703 3 
lymphocyte antigen 
CD5-like 
CD5L NM_005894 1 5 8136 1 
oral-facial-digital 
syndrome 1 
OFD1 NM_003611 X 14 21584 1 
WD repeat domain 78 WDR78 NM_024763 1 15 19908 1 
WD repeat domain 63 WDR63 NM_145172 1 20 25551 1 
Tctex1 domain 
containing 1 
FLJ4087
3 
(TCTEX
1D1) 
NM_152665 1 4 6853 1 
Tctex1 domain 
containing 4 
LOC343
521 
(TCTEX
1D4) 
NM_001013632 1 1 2373 1 
phosphatidylinositol 3-
kinase, catalytic, alpha 
PIK3CA NM_006218 3 10 18997 1 
3-a 
phosphatidylinositide-
dependent protein kinase 
1≠ 
PDPK1 
NM_031268,NM_00
2613 
16 10 18770 2 
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*trIDs: transcripts identification; †chr: chromosome; ‡Segs (n): number of 
segments; §Segs (bp): length (bp) of the screened gene regions; ||Transc (n): 
number of transcripts captured; ≠: more than one transcript was captured. 
 
  
retinitis pigmentosa 
GTPase regulator≠ 
RPGR 
NM_001034853,NM
_000328 
X 16 23170 2 
V-AKT murine thymoma 
viral oncogene homolog 
1≠ 
AKT1 
NM_001014432,NM
_005163,NM_00101
4431 
14 5 12302 3 
adenylate kinase 1 AK1 NM_000476 9 4 7436 1 
adenylate kinase 5 AK5 NM_174858 1 13 16363 1 
protein phosphatase 3, 
catalytic subunit, alpha 
isoform≠ 
PPP3CA 
NM_000944,NM_00
1130691,NM_00113
0692 
4 14 18690 3 
protein phosphatase 3, 
catalytic subunit, beta 
isoform 
PPP3CB NM_021132 10 10 14241 1 
protein phosphatase 3, 
catalytic subunit, gamma 
isoform 
PPP3CC NM_005605 8 10 14234 1 
galactosidase alpha GLA NM_000169 X 4 6783 1 
sphingomyelin 
phosphodiesterase 1, acid 
lysosomal≠ 
SMPD1 
NM_001007593,NM
_000543 
11 2 5555 2 
Radial spoke head 1 
homolog 
RSPH1 NM_080860 21 7 9041 1 
Radial spoke head 3 
homolog 
RSPH3 NM_031924 6 6 9567 1 
flap structure-specific 
endonuclease1 
FEN1 NM_004111 11 2 4251 1 
formyl peptide receptor-
like 1≠ 
FPR2 
NM_001005738,NM
_001462 
19 3 5045 2 
selectin P precursor SELP NM_003005 1 11 18226 1 
selectin E SELE NM_000450 1 3 12007 1 
paraoxonase 1 PON1 NM_000446 7 9 11442 1 
paraoxonase 3 PON3 NM_000940 7 8 9468 1 
paraoxonase 2≠ PON2 
NM_001018161,NM
_000305 
7 6 9561 2 
prosaposin≠ PSAP 
NM_002778,NM_00
1042465,NM_00104
2466 
10 8 13885 3 
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